<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">80443</article-id><article-id pub-id-type="doi">10.7554/eLife.80443</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>CCR4 and CCR7 differentially regulate thymocyte localization with distinct outcomes for central tolerance</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-281249"><name><surname>Li</surname><given-names>Yu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1893-9046</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-319343"><name><surname>Guaman Tipan</surname><given-names>Pablo</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0007-3127-7095</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-270520"><name><surname>Selden</surname><given-names>Hilary J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-270518"><name><surname>Srinivasan</surname><given-names>Jayashree</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9478-7518</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-319344"><name><surname>Hale</surname><given-names>Laura P</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-39745"><name><surname>Ehrlich</surname><given-names>Lauren IR</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1697-1755</contrib-id><email>lehrlich@austin.utexas.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00hj54h04</institution-id><institution>Department of Molecular Biosciences, The University of Texas at Austin</institution></institution-wrap><addr-line><named-content content-type="city">Austin</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00py81415</institution-id><institution>Department of Pathology, Duke University</institution></institution-wrap><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00hj54h04</institution-id><institution>Department of Oncology, LIVESTRONG Cancer Institutes, The University of Texas at Austin Dell Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Austin</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Zúñiga-Pflücker</surname><given-names>Juan Carlos</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03dbr7087</institution-id><institution>University of Toronto, Sunnybrook Research Institute</institution></institution-wrap><country>Canada</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Taniguchi</surname><given-names>Tadatsugu</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057zh3y96</institution-id><institution>University of Tokyo</institution></institution-wrap><country>Japan</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>02</day><month>06</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e80443</elocation-id><history><date date-type="received" iso-8601-date="2022-05-20"><day>20</day><month>05</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-06-01"><day>01</day><month>06</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-04-04"><day>04</day><month>04</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.04.03.486911"/></event></pub-history><permissions><copyright-statement>© 2023, Li, Guaman Tipan et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Li, Guaman Tipan et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-80443-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-80443-figures-v2.pdf"/><abstract><p>Central tolerance ensures autoreactive T cells are eliminated or diverted to the regulatory T cell lineage, thus preventing autoimmunity. To undergo central tolerance, thymocytes must enter the medulla to test their T-cell receptors (TCRs) for autoreactivity against the diverse self-antigens displayed by antigen-presenting cells (APCs). While CCR7 is known to promote thymocyte medullary entry and negative selection, our previous studies implicate CCR4 in these processes, raising the question of whether CCR4 and CCR7 play distinct or redundant roles in central tolerance. Here, synchronized positive selection assays, two-photon time-lapse microscopy, and quantification of TCR-signaled apoptotic thymocytes, demonstrate that CCR4 and CCR7 promote medullary accumulation and central tolerance of distinct post-positive selection thymocyte subsets in mice. CCR4 is upregulated within hours of positive selection signaling and promotes medullary entry and clonal deletion of immature post-positive selection thymocytes. In contrast, CCR7 is expressed several days later and is required for medullary localization and negative selection of mature thymocytes. In addition, CCR4 and CCR7 differentially enforce self-tolerance, with CCR4 enforcing tolerance to self-antigens presented by activated APCs, which express CCR4 ligands. Our findings show that CCR7 expression is not synonymous with medullary localization and support a revised model of central tolerance in which CCR4 and CCR7 promote early and late stages of negative selection, respectively, via interactions with distinct APC subsets.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>Autoimmune diseases occur when immune cells mistakenly identify the body’s own tissues as ‘foreign’ and attack them. To reduce the risk of this happening, the body has multiple ways of removing self-reactive immune cells, including T cells. One such way, known as central tolerance, occurs in the thymus – the organ where T cells develop.</p><p>In the center of the thymus – the medulla – specialized cells display fragments of the majority of proteins expressed by healthy cells throughout the body. Developing T cells enter the medulla, where they scan these specialized cells to determine if they recognize the presented protein fragments. If an immature T cell recognizes and binds to these ‘self-antigens’ too strongly, it is either destroyed, or it develops into a regulatory cell, capable of actively suppressing T cell responses to that self-antigen. This ensures that T cells won’t attack healthy cells in the body that make those self-antigens, and therefore, it is important that T cells enter the medulla and carry out this scanning process efficiently.</p><p>T cells are recruited to the medulla from the outer region of the thymus by chemical signals called chemokines. These signals are recognized by chemokine receptors on T cells, which are expressed at different times during T cell development. Previous work has shown that one of these receptors, called CCR7, guides T cells to the medulla. Although it was thought that CCR7 was solely responsible for this migration, prior work suggests another receptor, CCR4, may also contribute to T cell migration into the medulla and central tolerance.</p><p>To determine whether CCR7 and CCR4 play the same or different roles in central tolerance, Li, Tipan et al. used a combination of experimental methods, including live imaging of the thymus, to study T cell development in mice. The experiments revealed that CCR4 is expressed first, and this receptor alone guides immature T cells into the medulla and ensures that they are the first to be checked for self-reactivity. In contrast, CCR7 is expressed by more mature developing T cells two to three days later, ensuring they also accumulate within the medulla and become tolerant to self-antigens. Both receptors are required for protection from autoimmunity, with results suggesting that CCR4 and CCR7 promote tolerance against different tissues.</p><p>Taken together, the findings provide new information about the distinct requirement for CCR4 and CCR7 in guiding immature T cells into the medulla and ensuring central tolerance to diverse tissues. One outstanding question is whether defects in T cells entering the medulla earlier or later alter tolerance to distinct self-antigens and lead to different autoimmune diseases. Future work will also investigate whether these observations hold true in humans, potentially leading to therapies for autoimmune diseases.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>CCR4</kwd><kwd>CCR7</kwd><kwd>central tolerance</kwd><kwd>negative selection</kwd><kwd>chemokine receptors</kwd><kwd>thymocytes</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01AI104870</award-id><principal-award-recipient><name><surname>Ehrlich</surname><given-names>Lauren IR</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Two-photon microscopy, combined with chemotaxis assays, synchronized thymocyte selection studies, and flow cytometry analyses, reveal that CCR4 and CCR7 promote medullary entry and central tolerance of immature and mature post-positive selection thymocyte subsets, respectively, with distinct outcomes for central tolerance.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Self-tolerance of the T cell repertoire is established in thymus through the process of central tolerance, which encompasses both negative selection and regulatory T cell (Treg) induction (<xref ref-type="bibr" rid="bib38">Klein et al., 2014</xref>). To avoid autoimmunity, developing T cells must be broadly tolerized not only to ubiquitously expressed self-antigens, but also to proteins expressed by distinct differentiated cell types. The thymic medulla is a specialized environment in which central tolerance to such diverse self-antigens is enforced. After positive selection in the cortex, thymocytes migrate into the medulla, where they interact with medullary antigen-presenting cells (APCs), including thymic dendritic cells (DCs) and medullary thymic epithelial cells (mTECs). Collectively, these APCs enforce self-tolerance by presenting self-peptides from the majority of the proteome on MHC complexes, such that thymocytes expressing autoreactive T cell receptors undergo clonal deletion or diversion to the Treg lineage (<xref ref-type="bibr" rid="bib27">Ehrlich, 2016</xref>; <xref ref-type="bibr" rid="bib38">Klein et al., 2014</xref>; <xref ref-type="bibr" rid="bib39">Klein et al., 2019</xref>; <xref ref-type="bibr" rid="bib46">Lancaster et al., 2019</xref>). AIRE<sup>+</sup> mTECs express &gt;80% of the proteome, including <italic>Aire</italic>-dependent tissue restricted antigens (TRAs) that are otherwise expressed in only a few peripheral tissues (<xref ref-type="bibr" rid="bib1">Abramson and Anderson, 2017</xref>; <xref ref-type="bibr" rid="bib4">Anderson and Su, 2016</xref>; <xref ref-type="bibr" rid="bib51">Mathis and Benoist, 2007</xref>; <xref ref-type="bibr" rid="bib55">Meredith et al., 2015</xref>). DCs also present numerous self-antigens, including those acquired from mTECs, from circulation, or from peripheral tissues and trafficked into the thymus (<xref ref-type="bibr" rid="bib6">Atibalentja et al., 2009</xref>; <xref ref-type="bibr" rid="bib11">Bonasio et al., 2006</xref>; <xref ref-type="bibr" rid="bib40">Koble and Kyewski, 2009</xref>). The importance of inducing thymocyte tolerance to medullary self-antigens is evidenced by multi-organ autoimmunity that ensues in <italic>Aire</italic>-deficient mice and APECED patients (<xref ref-type="bibr" rid="bib3">Anderson et al., 2002</xref>; <xref ref-type="bibr" rid="bib28">Finnish-German APECED Consortium, 1997</xref>; <xref ref-type="bibr" rid="bib58">Nagamine et al., 1997</xref>), in whom thymic expression of TRAs is greatly diminished. Failure to express even a single medullary TRA can result in impaired tolerance and subsequent T cell-mediated autoimmune pathology (<xref ref-type="bibr" rid="bib24">DeVoss et al., 2006</xref>). Notably, individual TRAs are expressed by only 1–3% of <italic>Aire</italic><sup>+</sup> mTECs (<xref ref-type="bibr" rid="bib15">Brennecke et al., 2015</xref>; <xref ref-type="bibr" rid="bib55">Meredith et al., 2015</xref>; <xref ref-type="bibr" rid="bib66">Sansom et al., 2014</xref>), resulting in a sparse mosaic of self-antigen display throughout the medulla. Because thymocytes reside in the medulla for only 4–5 days (<xref ref-type="bibr" rid="bib52">McCaughtry et al., 2007</xref>), tight spatiotemporal regulation is required to ensure that post-positive selection thymocytes encounter the full spectrum of medullary self-antigens required to enforce self-tolerance.</p><p>To facilitate medullary entry after positive selection, thymocytes upregulate chemokine receptors that promote their directional migration toward medullary biased chemokine gradients (<xref ref-type="bibr" rid="bib10">Bleul and Boehm, 2000</xref>; <xref ref-type="bibr" rid="bib32">Hu et al., 2015a</xref>; <xref ref-type="bibr" rid="bib45">Lancaster et al., 2018</xref>; <xref ref-type="bibr" rid="bib63">Petrie and Zúñiga-Pflücker, 2007</xref>). Notably, CCR7 has been shown to play a critical role in directing chemotaxis of post-positive selection thymocytes toward the medulla, where CCR7 ligands are expressed, enhancing thymocyte accumulation within the medulla, enforcing negative selection to TRAs, and averting autoimmunity (<xref ref-type="bibr" rid="bib26">Ehrlich et al., 2009</xref>; <xref ref-type="bibr" rid="bib41">Kozai et al., 2017</xref>; <xref ref-type="bibr" rid="bib43">Kurobe et al., 2006</xref>; <xref ref-type="bibr" rid="bib59">Nitta et al., 2009</xref>; <xref ref-type="bibr" rid="bib71">Ueno et al., 2004</xref>). Given the significance of CCR7 in promoting thymocyte medullary entry, CCR7 expression is widely considered to be synonymous with thymocyte medullary localization. Based largely on this definition, recent studies indicate that despite the well-established role of the medulla in inducing central tolerance, ~75% of negative selection occurs in CCR7<sup>−</sup> ‘cortical’ thymocytes, while only 25% occurs in CCR7<sup>+</sup> ‘medullary’ cells (<xref ref-type="bibr" rid="bib14">Breed et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">Daley et al., 2013</xref>; <xref ref-type="bibr" rid="bib34">Hu et al., 2016</xref>). It has also been suggested that cortical negative selection may eliminate thymocytes reactive to ubiquitous self-antigens while medullary deletion tolerizes TRA-responsive cells. Our previous research implicates chemokine receptors other than CCR7 in promoting thymocyte medullary localization (<xref ref-type="bibr" rid="bib26">Ehrlich et al., 2009</xref>). We found that CCR4, which is upregulated by post-positive selection thymocytes, also promotes medullary entry and negative selection (<xref ref-type="bibr" rid="bib33">Hu et al., 2015b</xref>). These findings raise the question of whether CCR4 and CCR7 play distinct or redundant roles in promoting thymocyte medullary entry and central tolerance.</p><p>In this paper, we use a combination of approaches, including chemotaxis assays, two-photon live-cell microscopy, and synchronized positive selection assays, to distinguish the contributions of CCR4 versus CCR7 to thymocyte medullary entry and negative selection. We find that CCR4 is upregulated by thymocytes as early as a few hours after positive selection, while CCR7 is expressed days later by mature post-positive selection cells. CCR4 expression promotes chemotaxis and medullary entry of early post-positive selection thymocytes, which do not yet express CCR7. Initial CCR7 expression results in only moderate thymocyte chemotaxis toward CCR7 ligands and modest accumulation in the medulla, such that these thymocytes migrate in both the cortex and medulla. These findings indicate that CCR7 expression is not a definitive marker of medullary versus cortical localization. CCR7 is, however, required for robust accumulation of mature (CD4SP) thymocytes in the medulla. Notably, consistent with their differential activity in distinct thymocyte subsets, CCR4 and CCR7 are required in early and late phases of polyclonal negative selection, respectively. While CCR7 is known to promote tolerance to TRAs (<xref ref-type="bibr" rid="bib41">Kozai et al., 2017</xref>; <xref ref-type="bibr" rid="bib59">Nitta et al., 2009</xref>), we present evidence that CCR4 promotes tolerance to self-antigens presented by activated APCs. Collectively, our study establishes non-redundant roles for CCR4 and CCR7 in governing localization of post-positive selection thymocyte subsets and central tolerance.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>CCR4 is expressed by immature post-positive selection thymocyte subsets, while CCR7 expression is restricted to more mature thymocyte subsets</title><p>We first investigated expression of CCR4 and CCR7 by distinct thymocyte subsets using cell-surface markers that delineate developmental stages after positive selection (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="bibr" rid="bib68">Sinclair et al., 2013</xref>; <xref ref-type="bibr" rid="bib74">Xing et al., 2016</xref>). To validate the developmental trajectory of these thymocyte subsets, we analyzed their GFP expression levels in Rag2p-GFP mice, in which GFP expression is driven by the <italic>Rag2</italic> promoter. In this model, expression of GFP distinguishes newly generated thymocytes (GFP<sup>+</sup>) from recirculating T cells (GFP<sup>−</sup>), and declining GFP expression reflects time elapsed after positive selection, when the <italic>Rag2</italic> promoter becomes inactive (<xref ref-type="bibr" rid="bib13">Boursalian et al., 2004</xref>). In pre-positive selection CD4<sup>+</sup>CD8<sup>+</sup> double-positive (DP) CD3<sup>−</sup>CD69<sup>−</sup> thymocytes, the <italic>Rag2</italic> promoter is active, resulting in maximal GFP expression (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). After receiving a TCR signal, thymocytes upregulate CD3 and CD69 (<xref ref-type="bibr" rid="bib29">Fu et al., 2009</xref>), generating early post-positive selection DP CD3<sup>lo</sup>CD69<sup>+</sup> cells; the brief time elapsed after positive selection is indicated by continued high GFP expression by this subset (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). To further evaluate if DP CD3<sup>lo</sup>CD69<sup>+</sup> thymocytes represent post-positive selection thymocytes, as opposed to cells undergoing strong TCR signaling driving clonal deletion, we evaluated thymocyte subsets from <italic>Nr4a1<sup>GFP</sup></italic> mice, in which GFP levels reflect the strength of TCR signaling (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib57">Moran et al., 2011</xref>). Elevation of GFP expression by DP CD3<sup>lo</sup>CD69<sup>+</sup> cells, relative to DP CD3<sup>−</sup>CD69<sup>−</sup> cells, confirmed this subset was TCR signaled. Thymocytes rescued from negative selection express <italic>Nr4a1<sup>GFP</sup></italic> at levels comparable to thymic Tregs, which express self-reactive TCRs (<xref ref-type="bibr" rid="bib69">Stritesky et al., 2013</xref>). GFP levels were substantially lower in DP CD3<sup>lo</sup>CD69<sup>+</sup> cells than in CD25<sup>+</sup> CD4SPs, which are mostly Tregs (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Together, these data are consistent with DP CD3<sup>lo</sup>CD69<sup>+</sup> cells representing mainly post-positive selection DPs, and not strongly self-reactive thymocytes undergoing negative selection. Sequential maturation through CD4<sup>+</sup> single-positive semi-mature cells (CD4SP SM) and then CD4SP or CD8SP mature 1 (M1) and mature 2 (M2) subsets was confirmed by progressive reductions in GFP levels for both the CD4 and CD8 lineages (<xref ref-type="fig" rid="fig1">Figure 1B</xref>; <xref ref-type="bibr" rid="bib74">Xing et al., 2016</xref>). A distinct population of DP CD3<sup>+</sup>CD69<sup>+</sup> cells expressed lower levels of GFP than CD4SP SM cells (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), placing it temporally between CD4SP SM and CD8SP M1 cells (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Thus, we considered whether DP CD3<sup>+</sup>CD69<sup>+</sup> cells represent MHC-I-restricted thymocytes in the process of differentiating into CD8SP cells through co-receptor reversal downstream of the CD4SP SM stage (<xref ref-type="bibr" rid="bib17">Brugnera et al., 2000</xref>). Consistent with this possibility, DP CD3<sup>+</sup>CD69<sup>+</sup> cells were significantly reduced in <italic>B2m<sup>−/−</sup></italic> mice, in which positive selection of CD8SP thymocytes is abrogated, as is selection of innate iNKT cells and CD8αα+ IELps (<xref ref-type="bibr" rid="bib9">Bendelac et al., 1994</xref>; <xref ref-type="bibr" rid="bib65">Ruscher et al., 2017</xref>). Furthermore, DP CD3<sup>+</sup>CD69<sup>+</sup> cells were enriched in mice with a deletion spanning the MHC-II genes <italic>H2-Aa</italic>, <italic>H2-Eb1</italic>, and <italic>H2-Eb2 (MHCII<sup>−/−</sup></italic>) in which only MHC-I-restricted thymocytes are positively selected (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B, C</xref>). Together, these data demonstrate that DP CD3<sup>+</sup>CD69<sup>+</sup> cells are MHC-I restricted and have persisted for an intermediate time between CD4SP SM and CD8SP M1 cells after positive selection, consistent with a co-receptor reversing DP subset.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>CCR4 and CCR7 are expressed by immature and mature subsets of post-positive selection thymocytes, respectively.</title><p>(<bold>A</bold>) Flow cytometry gating scheme to delineate thymocyte subsets in Rag2p-GFP mice. Post-positive selection DP (CD3<sup>lo</sup>CD69<sup>+</sup> and CD3<sup>+</sup>CD69<sup>+</sup>), CD4SP (SM, M1, and M2), and CD8SP (M1 and M2) subsets are annotated. (<bold>B</bold>) Relative Rag2p-GFP Geometric Mean Fluorescent Intensity (GMFI) of each subset normalized to pre-positive selection DP CD3<sup>−</sup>CD69<sup>−</sup> cells. Individual data points represent average GFP GMFI of the indicated subset from each mouse. (<bold>C</bold>) Representative flow cytometry plots showing CCR4 and CCR7 expression by post-positive selection thymocyte subsets. (<bold>D</bold>) Quantification of the percentage of cells of the indicated subset that express CCR4, CCR7, or both chemokine receptors. For (<bold>B</bold>) and (<bold>D</bold>), data were compiled from four independent experiments (mean ± standard error of the mean [SEM]; <italic>N</italic> = 10 mice).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80443-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>DP CD3<sup>lo</sup>CD69<sup>+</sup> cells are consistent with post-positive selection DPs and DP CD3<sup>+</sup>CD69<sup>+</sup> cells represent co-receptor reversing MHCI-restricted thymocytes.</title><p>(<bold>A</bold>) Quantification of the GFP mean fluorescence intensity (MFI) of the indicated thymocyte subsets from <italic>Nr4a1<sup>GFP</sup></italic> mice. Data were compiled from three independent experiments (mean ± SEM; <italic>Nr4a1<sup>GFP+</sup> N</italic> = 4 mice, <italic>Nr4a1<sup>GFP−</sup> N</italic> = 3 mice). (<bold>B</bold>) Flow cytometry plots showing the absence of DP CD3<sup>+</sup>CD69<sup>+</sup> thymocytes in <italic>B2m<sup>−/−</sup></italic>, but not <italic>MHCII<sup>−/−</sup></italic> mice. (<bold>C</bold>) Quantification of the frequency of DP CD3<sup>+</sup>CD69<sup>+</sup> in all DP thymocytes from wild-type, <italic>B2m<sup>−/−</sup></italic>, and <italic>MHCII<sup>−/−</sup></italic> mice. One-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons correction was used for statistical analysis (mean ± SEM; *p &lt; 0.05, ***p &lt; 0.001).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80443-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>CCR7 expression on developing thymocytes begin at the CD4SP SM stage.</title><p>(<bold>A</bold>) Representative flow cytometry overlays showing CCR4 and CCR7 expression by post-positive selection thymocyte subsets from WT and <italic>Ccr7<sup>−/−</sup></italic> mice, respectively. (<bold>B</bold>) Quantification of the CCR7 MFI within each subset from data in A (mean ± SEM; <italic>N</italic> = 4 mice of each genotype). (<bold>C, D</bold>) Quantification of CCR7 and CCR4 MFIs for each thymocyte subset after incubation at 37°C for the indicated times, prior to antibody staining at 4°C. Data were compiled from two independent experiments (mean ± SEM; <italic>N</italic> = 4 mice).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80443-fig1-figsupp2-v2.tif"/></fig></fig-group><p>Having delineated the temporal sequence of thymocyte development post-positive selection, we quantified expression of CCR4 and CCR7 by each subset. CCR4 is upregulated by the majority of early post-positive selection DP CD3<sup>lo</sup>CD69<sup>+</sup> thymocytes, which do not yet express CCR7 (<xref ref-type="fig" rid="fig1">Figure 1C, D</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A, B</xref>). CCR7 is subsequently expressed at high levels by ~40% CD4SP SM cells, and CCR4 expression persists on this subset (<xref ref-type="fig" rid="fig1">Figure 1C, D</xref>). In comparison to <italic>Ccr7</italic><sup>−/−</sup> cells, low-level expression of CCR7 can be detected on additional <italic>Ccr7</italic><sup>+/+</sup> CD4SP SM cells, consistent with initial upregulation of CCR7 by this subset (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A, B</xref>). Expression of CCR4 and CCR7 by MHC-I-restricted DP CD3<sup>+</sup>CD69<sup>+</sup> cells is similar to that of CD4SP SM cells, with slightly more CCR7 and less CCR4 (<xref ref-type="fig" rid="fig1">Figure 1C, D</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A, B</xref>). As thymocytes mature through CD4SP and CD8SP M1 and M2 stages, CCR4 is progressively downregulated. CCR7 expression peaks in both CD4SP and CD8SP M1 subsets and is diminished in M2 cells (<xref ref-type="fig" rid="fig1">Figure 1C, D</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A, B</xref>). Because cell-surface expression of CCR7 on mature CD4<sup>+</sup> T cells can be downregulated due to ligand-induced internalization of the chemokine receptor (<xref ref-type="bibr" rid="bib16">Britschgi et al., 2008</xref>), we tested whether receptor internalization could have obscured detection of CCR7 or CCR4 on ex vivo thymocyte subsets. Thymocytes were incubated at 37°C for up to 2 hr, to allow re-expression of internalized receptors, before immunostaining with anti-CCR7 and anti-CCR4 antibodies. Increased expression of cell-surface CCR7 or CCR4 was not detected with increasing incubation time (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C, D</xref>). These findings confirm that CCR4 expression is an early indicator of positive selection at the DP stage, while CCR7 expression is upregulated later by more mature CD4SP and CD8SP subsets.</p></sec><sec id="s2-2"><title>Early post-positive selection thymocytes undergo chemotaxis toward CCR4 ligands, while more mature subsets respond to CCR7 ligands</title><p>We next determined whether expression of CCR4 and CCR7 corresponds to thymocyte chemotactic responses to their respective ligands. DP CD3<sup>lo</sup>CD69<sup>+</sup> cells, which express CCR4 but not CCR7, underwent chemotaxis in response to the CCR4 ligand CCL22, but not the CCR7 ligands CCL19 or CCL21 (<xref ref-type="fig" rid="fig2">Figure 2A–D</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). CCL22-induced chemotaxis of all subsequent post-positive selection thymocytes, except the most mature M2 thymocyte subsets (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>), largely in keeping with CCR4 expression patterns. Although CD4SP SM and DP CD3+CD69+ subsets expressed CCR7 (<xref ref-type="fig" rid="fig1">Figure 1C</xref>), CCR7-mediated chemotaxis of these subsets did not reach statistical significance when compared to all thymocyte subsets (<xref ref-type="fig" rid="fig2">Figure 2C, D</xref>). However, when considered separately, moderate CCR7-mediated chemotaxis of these subsets was revealed, although DP CD3<sup>lo</sup>CD69<sup>+</sup> cells still did not undergo CCR7-mediated chemotaxis (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Consistent with expression of CCR7 by more mature thymocyte subsets, the CCR7 ligands CCL19 and CCL21 induced highly efficient chemotaxis of mature CD4SP and CD8SP M1 and M2 subsets (<xref ref-type="fig" rid="fig2">Figure 2C, D</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>CCR4 and CCR7 promote chemotaxis of immature and mature post-positive selection thymocyte subsets, respectively.</title><p>Transwell assays were used to quantify chemotaxis of thymocyte subsets to the indicated concentrations of the CCR4 ligands CCL17 (<bold>A</bold>) and CCL22 (<bold>B</bold>) and the CCR7 ligands CCL19 (<bold>C</bold>) and CCL21 (<bold>D</bold>). Migration index was calculated as the frequency of input cells of each subset that migrated toward the chemokine relative to the frequency of input cells that migrated in the absence of chemokine (Blank). Data were compiled from three independent experiments with triplicate wells per assay. Two-way ANOVA with Dunnett’s multiple comparisons correction was used for statistical analysis (mean ± SEM; *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80443-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Chemokine signaling is not diminished in CD4SP SM thymocytes.</title><p>(<bold>A</bold>) Migration indices from data in <xref ref-type="fig" rid="fig2">Figure 2</xref> for DP CD3<sup>lo</sup>CD69<sup>+</sup>, CD4SP SM, and DP CD3<sup>lo</sup>CD69<sup>+</sup> were analyzed separately to compare the relative efficiency of CCR4 and CCR7 ligands at inducing chemotaxis of each subset. Ordinary one-way ANOVA with Dunnett’s multiple comparisons corrections was used for statistical analysis (mean ± SEM; *p &lt; 0.05, **p &lt; 0.01, ****p &lt; 0.0001).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80443-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>CD4SP SM thymocytes migrate toward CCL25 and CCL22 is localized in the medulla.</title><p>(<bold>A</bold>) Transwell assays were used to quantify chemotaxis of thymocyte subsets to the indicated concentrations of the CCR9 ligand, CCL25. Migration index was calculated as the frequency of input cells of each subset that migrated toward the chemokine relative to the frequency of input cells that migrated in the absence of chemokine (Blank). Data were compiled from three independent experiments with triplicate wells per assay. Two-way ANOVA with Dunnett’s multiple comparisons correction was used for statistical analysis (mean ± SEM; *p &lt; 0.05, **p &lt; 0.01, ****p &lt; 0.0001). (<bold>B</bold>) Representative confocal images of CCL22 (green), CD11c (red), and CD31 (purple) on immunostained cryosections from WT thymus. The cortex (C) and medulla (M) are demarcated by white dotted lines. Bars, 100 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80443-fig2-figsupp2-v2.tif"/></fig></fig-group><p>A recent study indicated that expression of the chemokine receptor CXCR4 must be extinguished before post-positive selection thymocytes can leave the cortex, where CXCL12 is expressed by cortical thymic epithelial cells, to migrate into the medulla (<xref ref-type="bibr" rid="bib36">Kadakia et al., 2019</xref>). Thus, we sought to place CXCR4 expression and function into context with CCR4 and CCR7. CXCR4 expression decreased after positive selection, but all post-positive selection subsets continued to express CXCR4 (<xref ref-type="fig" rid="fig3">Figure 3A, B</xref>), and all except for CD4SP SM and DP CD3<sup>+</sup>CD69<sup>+</sup> subsets underwent chemotaxis in response to CXCL12 (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Although the earliest post-positive selection thymocyte subsets exhibited reduced CXCR4 responsiveness, perhaps allowing them to exit the cortex, the ability to respond to CXCR4 signals does not preclude medullary localization, as evidenced by CXCR4-mediated chemotaxis of medullary CD4SP and CD8SP M2 cells. Taken together, chemotaxis assays show that early post-positive selection DP CD3<sup>lo</sup>CD69<sup>+</sup> thymocytes are responsive to CCR4 but not CCR7 ligands, with low responsiveness to CXCR4 ligands. At the next stage, CD4SP SM cells also undergo chemotaxis toward CCR4 ligands, and begin to migrate at a low level toward CCR7 ligands, but not to CXCR4 ligands. As thymocytes mature to the CD4SP and CD8SP M1 and M2 stages, they progressively gain the ability to respond robustly to CCR7 ligands, regain CXCR4 responsiveness, and lose responsiveness to CCR4 ligands (<xref ref-type="fig" rid="fig3">Figure 3D</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Persistent CXCR4 expression was detected on post-positive selection thymocytes, and CXCR4 activity declines only in intermediate subsets.</title><p>(<bold>A</bold>) Representative flow cytometry plots showing CXCR4 surface expression by the indicated thymocyte subsets, compared to isotype control stains. (<bold>B</bold>) Quantification of relative GMFI of CXCR4 for the indicated thymocyte subsets (mean ± SEM; <italic>N</italic> = 10). (<bold>C</bold>) Transwell assays were used to quantify chemotaxis of thymocyte subsets to the indicated concentrations of CXCL12. Migration index was calculated as the frequency of input cells of each subset that migrated toward the chemokine relative to the frequency of input cells that migrated in the absence of chemokine (Blank). Data were compiled from three independent experiments with triplicate wells per assay. Two-way ANOVA with Dunnett’s multiple comparisons correction was used for statistical analysis (mean ± SEM; *p &lt; 0.05, **p &lt; 0.01, ****p &lt; 0.0001). (<bold>D</bold>) Graphical summary showing relative expression and chemotactic activity of CXCR4, CCR4, and CCR7 on post-positive selection thymocyte subsets based on data in <xref ref-type="fig" rid="fig1">Figures 1</xref>—<xref ref-type="fig" rid="fig3">3</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80443-fig3-v2.tif"/></fig><p>Initial expression of CCR7 by CD4SP SM thymocytes does not result in strong chemotaxis to CCR7 ligands (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), and expression of CXCR4 by this subset does not enable detectable chemotaxis toward CXCL12 (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), highlighting a temporal disconnect between chemokine receptor expression and function on maturing post-positive selection thymocytes. We considered the possibility that CD4SP SM cells could be intrinsically unable to respond to chemokine receptor signaling. However, these cells responded efficiently to CCR4 ligands (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), and they underwent chemotaxis to the CCR9 ligand CCL25 at levels comparable to DP CD3<sup>lo</sup>CD69<sup>+</sup> cells (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>), consistent with a previous study showing CCL25 induces migration of most thymocyte subsets (<xref ref-type="bibr" rid="bib19">Campbell et al., 1999</xref>). Thus, regulation of thymocyte responsiveness to chemokine receptors is more complex than altered cell-surface expression levels.</p><p>CCL21a establishes a chemokine gradient that drives accumulation of CD4SP thymocytes in the medulla (<xref ref-type="bibr" rid="bib41">Kozai et al., 2017</xref>; <xref ref-type="bibr" rid="bib70">Ueno et al., 2002</xref>; <xref ref-type="bibr" rid="bib71">Ueno et al., 2004</xref>). Because we found that functional CCR4 is expressed by early post-positive selection DP thymocytes, we examined whether CCL22 could establish a similar chemokine gradient to recruit these CCR4-responsive cells into the medulla. Immunofluorescence analysis revealed that CCL22 is expressed predominantly in the medulla (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>), consistent with a potential role in inducing medullary entry of early post-positive selection thymocytes.</p></sec><sec id="s2-3"><title>The timing of CCR4 upregulation following positive selection correlates with thymocyte medullary entry</title><p>Given that the majority of early post-positive selection DP thymocytes respond to CCR4 but not CCR7 ligands, we sought to determine how rapidly CCR4 versus CCR7 are upregulated following initiation of positive selection and to assess whether expression of either receptor correlates with the timing of medullary entry. To accomplish these goals, we used a synchronized positive selection thymic slice assay, coupled with flow cytometry or two-photon microscopy (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). OT-II<sup>+</sup> <italic>Rag2<sup>−/−</sup> MHCII<sup>−/−</sup></italic> mice served as a source of pre-positive selection DP thymocytes that did not yet express CCR4 or CCR7 due to lack of positive selection in the absence of MHC-II expression (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). OT-II<sup>+</sup> <italic>Rag2<sup>−/−</sup> MHCII<sup>−/−</sup></italic> thymocytes were fluorescently labeled prior to culturing on MHC-II-sufficient, positively selecting (wild-type [WT or pCX-EGFP]) or non-positively selecting (<italic>MHCII<sup>−/−</sup></italic>) live thymic slices. At various time points, expression of CCR4 and CCR7 by OT-II thymocytes in the thymic slices was assayed by flow cytometry, or medullary entry was quantified by two-photon live-cell microscopy (<xref ref-type="fig" rid="fig4">Figure 4A</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Rapid upregulation of CCR4 following positive selection of OT-II thymocytes correlates with medullary entry.</title><p>(<bold>A</bold>) Experimental schematic of synchronized thymic slice positive selection assays to determine the timing of CCR4 and CCR7 expression by flow cytometry and medullary entry by two-photon microscopy. (<bold>B</bold>) Representative flow cytometry plots showing CCR4 and CCR7 expression of OT-II<sup>+</sup> <italic>Rag2</italic><sup>−/−</sup><italic>MHCII</italic><sup>−/−</sup> thymocytes added to thymic slices (left) and analyzed 24 hr after incubation in WT or <italic>MHCII</italic><sup>−/−</sup> slices, as indicated (right). (<bold>C</bold>) Percentages of CCR4<sup>+</sup> and CCR4<sup>+</sup>CCR7<sup>+</sup> OT-II<sup>+</sup> thymocytes in thymic slices of the indicated genotypes at the indicated time points. Data were compiled from three experiments with triplicate slices each. Mixed-effect analysis with Šídák’s multiple comparisons correction was used for statistical analysis (mean ± SEM; *p &lt; 0.05, **p &lt; 0.01). (<bold>D</bold>) Representative maximum intensity projections of two-photon imaging data showing a pCX-EGFP thymic slice (green) containing CMTPX-labeled OT-II<sup>+</sup> <italic>Rag2<sup>−/−</sup> MHCII</italic><sup>−/−</sup> thymocytes (red) at 1.5 and 12 hr after thymocytes were added to the slices. Medullary and cortical volumes were demarcated as indicated by the masked regions. Bars, 100 µm. (<bold>E</bold>) Quantification of medullary density of OT-II<sup>+</sup> <italic>Rag2<sup>−/−</sup> MHCII</italic><sup>−/−</sup> thymocytes at indicated time points after incubation on pCX-EGFP thymic slices. Individual data points represent relative medullary input cell densities from each video compared to the average of medullary densities from all 1.5 hr videos. Data were compiled from four time-course experiments. One-way ANOVA with Tukey’s multiple comparison correction was used for statistical analysis (mean ± SEM; *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80443-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Rapid upregulation of CCR4 following positive selection of OT-I thymocytes correlates with medullary entry.</title><p>(<bold>A</bold>) Representative flow cytometry plots of CCR4 and CCR7 expression by pre-positive selection OT-I<sup>+</sup> <italic>Rag2<sup>−/−</sup></italic> thymocytes from <italic>B2m<sup>−/−</sup></italic> hosts that were added to thymic slices (left) or analyzed 24 hr after incubation in WT or <italic>B2m<sup>−/−</sup></italic> slices, as indicated (right). (<bold>B</bold>) Percentages of CCR4<sup>+</sup>, CCR4<sup>+</sup>CCR7<sup>+</sup>, CCR7<sup>+</sup>, or CD8SP OT-I<sup>+</sup> <italic>Rag2<sup>−/−</sup></italic> thymocyte after incubation on thymic slices of the indicated genotypes for the indicated time period up to 24 hr. (<bold>C</bold>) Percentages of CD8SP or CCR7<sup>+</sup> OT-I<sup>+</sup> <italic>Rag2</italic><sup>−/−</sup> thymocytes at 48 and 72 hr time points after incubation on thymic slices of the indicated genotypes. Data for B and C were compiled from three OT-I<sup>+</sup> <italic>Rag2<sup>−/−</sup></italic> BM -&gt; <italic>B2m<sup>−/−</sup></italic> experiments, with triplicate slices per experiment. Mixed-effect analysis with Šídák’s multiple comparisons correction were used for statistical analysis (mean ± SEM; *p &lt; 0.05, **p &lt; 0.01, ***p&lt;0.001, ****p &lt; 0.0001). (<bold>D</bold>) Representative maximum intensity projections of two-photon imaging data showing a pCX-EGFP thymic slice (green) containing CMTPX-labeled OT-I<sup>+</sup> <italic>Rag2<sup>−/−</sup></italic> BM -&gt; <italic>B2m<sup>−/−</sup></italic> thymocytes (red) at 1.5 and 12 hr after thymocytes were added to the slices. Medullary and cortical volumes were demarcated as indicated by the masked regions. Bars, 100 µm. (<bold>E</bold>) Quantification of medullary density of OT-I<sup>+</sup> <italic>Rag2<sup>−/−</sup></italic> cells at the indicated time points. Individual data points represent medullary density calculated from each video, relative to the average medullary density of all videos taken at 1.5 hr. Data were compiled from three time-course experiments. One-way ANOVA with Tukey’s multiple comparisons correction was used for statistical analysis (mean ± SEM; *p &lt; 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80443-fig4-figsupp1-v2.tif"/></fig></fig-group><p>OT-II<sup>+</sup> <italic>Rag2<sup>−/−</sup> MHCII<sup>−/−</sup></italic> DP cells upregulated CCR4 as early as 3 hr after being introduced onto positively selecting thymic slices (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). The frequency of CCR4<sup>+</sup> cells continued to increase over 24 hr on WT slices. Positive selection was required for initiation of CCR4 expression, as demonstrated by the failure to upregulate CCR4 on non-selecting <italic>MHCII<sup>−/−</sup></italic> slices. CCR7 was not upregulated within 24 hr of initiating positive selection (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). When labeled OT-II<sup>+</sup> <italic>Rag2<sup>−/−</sup> MHCII<sup>−/−</sup></italic> thymocytes were introduced into positively selecting pCX-EGFP thymic slices and imaged by two-photon microscopy, they were initially localized to the cortex, consistent with our previous findings that pre-positive selection thymocytes cannot access the medulla (<xref ref-type="video" rid="video1">Video 1</xref>; <xref ref-type="bibr" rid="bib26">Ehrlich et al., 2009</xref>). By 9–12 hr after positive selection, OT-II<sup>+</sup> thymocytes entered the medulla, as evidenced by a significant increase in medullary density (<xref ref-type="fig" rid="fig4">Figure 4D, E</xref>; <xref ref-type="video" rid="video2">Video 2</xref>). As CCR7 is not yet expressed by these cells (<xref ref-type="fig" rid="fig4">Figure 4C</xref>), CCR4 likely drives medullary entry of early post-positive selection thymocytes.</p><media mimetype="video" mime-subtype="mp4" xlink:href="elife-80443-video1.mp4" id="video1"><label>Video 1.</label><caption><title>Two-photon live imaging of OT-II<sup>+</sup> <italic>Rag2<sup>−/−</sup> MHCII<sup>−/−</sup></italic> input thymocytes (red) migrating in a pCX-EGFP thymic slice (green) 1.5 hr after addition to positively selecting thymic slices, as shown in <xref ref-type="fig" rid="fig3">Figure 3D</xref>.</title><p>Images were acquired for 15 min at 15-s time intervals through a depth of 40 µm, and maximum intensity projections are shown.</p></caption></media><media mimetype="video" mime-subtype="mp4" xlink:href="elife-80443-video2.mp4" id="video2"><label>Video 2.</label><caption><title>Two-photon live imaging of OT-II<sup>+</sup> <italic>Rag2<sup>−/−</sup> MHCII<sup>−/−</sup></italic> input thymocytes (red) migrating in a pCX-EGFP thymic slice (green) 12 hr after addition to positively selecting thymic slices, as shown in <xref ref-type="fig" rid="fig3">Figure 3D</xref>.</title><p>Images were acquired for 15 min at 15-s time intervals through a depth of 40 µm, and maximum intensity projections are shown.</p></caption></media><p>To test if the timing of CCR4 and CCR7 upregulation and medullary entry are comparable for MHC-I-restricted thymocytes, we carried out similar experiments using pre-positive selection OT-I<sup>+</sup> <italic>Rag2<sup>−/−</sup></italic> thymocytes that matured in the non-selecting thymuses of <italic>β2m<sup>−/−</sup></italic> hosts. Although OT-I positive selection was largely inhibited in these bone marrow chimeras, about 10% of the DP cells expressed CCR4 at baseline (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A, B</xref>). Nonetheless, CCR4 was upregulated as early as 3 hr after initiating positive selection in WT thymic slices, but not in non-selecting <italic>β2m<sup>−/−</sup></italic> slices and increased over 24 hr (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A, B</xref>). CCR7 was not expressed during the first 24 hr after initiation of positive selection and only became detectable as CD8SP cells differentiated at the 72 hr time point (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B, C</xref>), consistent with prior observations (<xref ref-type="bibr" rid="bib49">Lutes et al., 2021</xref>). Furthermore, two-photon imaging of pre-selection OT-I<sup>+</sup> <italic>Rag2<sup>−/−</sup></italic> thymocytes within the cortex and medulla of thymic slices showed that despite medullary entry of some thymocytes at 1.5 hr (<xref ref-type="video" rid="video3">Video 3</xref>), likely due to the observed baseline CCR4 expression in this model, the medullary density of OT-I thymocytes increased significantly by 12 hr after the initiation of positive selection (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D, E</xref>; <xref ref-type="video" rid="video4">Video 4</xref>).</p><media mimetype="video" mime-subtype="mp4" xlink:href="elife-80443-video3.mp4" id="video3"><label>Video 3.</label><caption><title>Two-photon live imaging of OT-I<sup>+</sup> <italic>Rag2<sup>−/−</sup></italic> input thymocytes from a <italic>B2m<sup>−/−</sup></italic> bone marrow chimera host (red) migrating in a pCX-EGFP thymic slice (green) 1.5 hr after addition to positively selecting thymic slices, as shown in <xref ref-type="fig" rid="fig4">Figure 4A</xref>.</title><p>Images were acquired for 15 min at 15-s time intervals through a depth of 40 µm, and maximum intensity projections are shown.</p></caption></media><media mimetype="video" mime-subtype="mp4" xlink:href="elife-80443-video4.mp4" id="video4"><label>Video 4.</label><caption><title>Two-photon live imaging of OT-I<sup>+</sup> <italic>Rag2<sup>−/−</sup></italic> input thymocytes from a <italic>B2m<sup>−/−</sup></italic> bone marrow chimera host (red) migrating in a pCX-EGFP thymic slice (green) 12 hr after addition to positively selecting thymic slices, as shown in Figure 4A.</title><p>Images were acquired for 15 min at 15-s time intervals through a depth of 40 µm, and maximum intensity projections are shown.</p></caption></media><p>Together, these findings show that both MHC-I- and MHC-II-restricted thymocytes upregulate CCR4 within a few hours of the initiation of positive selection and accumulate significantly in the medulla by 9–12 hr. Thymocyte medullary entry precedes CCR7 upregulation, which does not occur until 48–72 hr after positive selection. The kinetics of CCR4 upregulation are consistent with a role for CCR4 in promoting early medullary entry of positively selected thymocytes. However, CCR7 is known to be required for efficient medullary entry of SP thymocytes (<xref ref-type="bibr" rid="bib26">Ehrlich et al., 2009</xref>; <xref ref-type="bibr" rid="bib43">Kurobe et al., 2006</xref>), raising the possibility that these two chemokine receptors promote medullary localization of different thymocyte subsets.</p></sec><sec id="s2-4"><title>CCR4 and CCR7 are required for medullary accumulation of distinct post-positive selection thymocyte subsets</title><p>To test our hypothesis that CCR4 and CCR7 are required for medullary accumulation of distinct post-positive selection thymocytes, we purified thymocyte subsets by Fluorescence Activated Cell Sorting (FACS) from WT, <italic>Ccr4<sup>−/−</sup></italic>, <italic>Ccr7<sup>−/−</sup></italic>, and <italic>Ccr4<sup>−/−</sup>; Ccr7<sup>−/−</sup></italic> (DKO) mice, labeled them with red or blue fluorescent dyes, and allowed them to migrate in pCX-EGFP live thymic slices. Two-photon time-lapse microscopy was used to image the sorted cells, so we could determine their migratory properties and densities in the medulla versus cortex (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). EGFP is expressed ubiquitously in pCX-EGFP mice, such that the cortex and medulla of thymic slices can be distinguished by differences in stromal cell morphology and EGFP intensity (<xref ref-type="fig" rid="fig5">Figure 5A</xref>; <xref ref-type="bibr" rid="bib26">Ehrlich et al., 2009</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>CCR4 and CCR7 are required for medullary accumulation of distinct post-positive selection thymocyte subsets.</title><p>(<bold>A</bold>) Representative maximum intensity projections of two-photon imaging data showing pCX-EGFP thymic slices (green) containing CMTPX (red)- and Indo-1 AM (blue)-labeled FACS sorted DP CD3<sup>lo</sup>CD69<sup>+</sup>, CD4SP SM, or CD4SP M1 + M2 cells from WT or <italic>Ccr4<sup>−/−</sup></italic> mice, as indicated, imaged 1–4 hr after slice entry. The cortex and medulla are demarcated by white dotted lines, and cell tracks are color encoded for elapsed imaging time. Bars, 100 µm. (<bold>B</bold>) Medullary-to-cortical thymocyte density ratios were quantified from two-photon imaging data as in (<bold>A</bold>), with individual data points representing ratios from individual videos. (<bold>C</bold>) Paired analysis of medullary-to-cortical density ratios of WT versus <italic>Ccr4<sup>−/−</sup></italic>, WT versus <italic>Ccr7<sup>−/−</sup></italic>, or <italic>Ccr7<sup>−/−</sup></italic> versus DKO thymocyte subsets imaged simultaneously within the same slices, with individual data points representing ratios from single videos. Paired datasets are taken from the same data shown in (<bold>B</bold>), and paired <italic>t</italic>-tests were used for statistical analysis (**p &lt; 0.01, ***p &lt; 0.001). Quantification of (<bold>D</bold>) average thymocyte track speeds and (<bold>E</bold>) average track straightness from imaging data reported in (<bold>B</bold>). Individual data points represent average track speeds or straightness of thymocytes of the indicated genotype in individual videos. For (<bold>B</bold>), (<bold>D</bold>), and (<bold>E</bold>), data were compiled from 19 independent experiments. One-way ANOVA with Tukey’s multiple comparisons correction was used for statistical analysis (mean ± SEM; *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt;0.0001).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80443-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Experimental approach to test if CCR4 and CCR7 are required for medullary entry of distinct FACS purified post-positive selection thymocyte subsets that differentially express CCR4 and CCR7.</title><p>(<bold>A</bold>) Experimental schematic of two-photon imaging of sorted, fluorescently labeled post-positive selection thymocyte subsets. WT cells were imaged in the same slices with <italic>Ccr4</italic><sup>−/−</sup> or <italic>Ccr7</italic><sup>−/−</sup> cells, or <italic>Ccr7</italic><sup>−/−</sup> cells were imaged in the same slices with DKO cells. Dyes were swapped between different experiments, and we did not find that use of CMTPX versus Indo-1 altered the results. Representative flow cytometry plots showing (<bold>B</bold>) the gating scheme for sorting DP CD3<sup>lo</sup>CD69<sup>+</sup>, CD4SP SM, and CD4SP M1 + M2 subsets for two-photon imaging, and (<bold>C</bold>) CCR4 and CCR7 expression of FACS purified thymocyte subsets from a WT mouse.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80443-fig5-figsupp1-v2.tif"/></fig></fig-group><p>Purified WT DP CD3<sup>lo</sup>CD69<sup>+</sup> cells entered and migrated within the medulla, accumulating at a twofold higher density than in the cortex (<xref ref-type="fig" rid="fig5">Figure 5A, B</xref>; <xref ref-type="video" rid="video5">Video 5</xref>). As expected, the majority of the sorted early post-positive selection cells expressed CCR4, but not CCR7 (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B, C</xref>). Medullary enrichment of this subset was abolished when the cells were purified from <italic>Ccr4<sup>−/−</sup></italic> or DKO mice, but <italic>Ccr7</italic> deficiency did not diminish their medullary accumulation (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Paired analyses of WT versus <italic>Ccr4<sup>−/−</sup></italic> and <italic>Ccr7</italic><sup>−/−</sup> versus DKO DP CD3<sup>lo</sup>CD69<sup>+</sup> cells imaged together in the same slices confirmed that <italic>Ccr4</italic> deficiency significantly impaired medullary accumulation of this early post-positive selection DP subset irrespective of <italic>Ccr7</italic> genotype, but genetic deficiency of <italic>Ccr7</italic> at this stage did not alter medullary accumulation (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Altogether, CCR4 is required for the twofold accumulation of DP CD3<sup>lo</sup>CD69<sup>+</sup> cells in the medulla relative to the cortex.</p><media mimetype="video" mime-subtype="mp4" xlink:href="elife-80443-video5.mp4" id="video5"><label>Video 5.</label><caption><title>Two-photon live imaging of WT (red) and <italic>Ccr4<sup>−/−</sup></italic> (blue) FACS sorted DP CD3<sup>lo</sup>CD69<sup>+</sup> thymocytes migrating in pCX-EGFP thymic slices (green), as shown in <xref ref-type="fig" rid="fig4">Figure 4A</xref>.</title><p>Images were acquired for 15 min at 15-s time intervals through a depth of 40 µm, and maximum intensity projections with and without cell tracks, color coded for elapsed imaging time, are shown side by side.</p></caption></media><p>Despite the fact that roughly half of the purified CD4SP SM cells expressed CCR7 (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B, C</xref>), which is considered to be a hallmark of thymocyte medullary entry, accumulation of these cells within the medulla did not further increase, but instead remained at a twofold medullary: cortical density ratio, comparable to that of DPCD3<sup>lo</sup>CD69<sup>+</sup> cells (<xref ref-type="fig" rid="fig5">Figure 5A, B</xref>; <xref ref-type="video" rid="video6">Video 6</xref>). Medullary accumulation of this subset was significantly reduced by CCR4 deficiency, regardless of the <italic>Ccr7</italic> genotype (<xref ref-type="fig" rid="fig5">Figure 5B, C</xref>), indicating an important role for CCR4 in promoting medullary localization of CD4SP SM cells. In addition, paired analysis of <italic>Ccr7<sup>−/−</sup></italic> versus WT CD4SP SM cells imaged together in the same slices showed that CCR7 also contributes to medullary accumulation of CD4SP SM cells (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Together, these data indicate that CCR4 and CCR7 cooperate to promote medullary accumulation of CD4SP SM thymocytes.</p><media mimetype="video" mime-subtype="mp4" xlink:href="elife-80443-video6.mp4" id="video6"><label>Video 6.</label><caption><title>Two-photon live imaging of WT (red) and <italic>Ccr4<sup>−/−</sup></italic> (blue) FACS sorted CD4SP SM thymocytes migrating in pCX-EGFP thymic slices (green), as shown in <xref ref-type="fig" rid="fig4">Figure 4A</xref>.</title><p>Images were acquired for 15 min at 15-s time intervals through a depth of 40 µm, and maximum intensity projections with and without cell tracks, color coded for elapsed imaging time, are shown side by side.</p></caption></media><p>CD4SP M1 + M2 thymocytes, the majority of which express only CCR7 (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>), accumulated in the medulla to a greater extent than either of the previous subsets, with a ~4- to 5-fold medullary:cortical density ratio (<xref ref-type="fig" rid="fig5">Figure 5B, C</xref>; <xref ref-type="video" rid="video7">Videos 7</xref> and <xref ref-type="video" rid="video8">8</xref>), consistent with the high migration index of these cells to CCR7 ligands (<xref ref-type="fig" rid="fig2">Figure 2C, D</xref>). CCR4 deficiency did not significantly impact medullary accumulation of this subset (<xref ref-type="fig" rid="fig5">Figure 5B, C</xref>), consistent with the lack of responsiveness of M2 cells to CCR4 ligands (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). However, the trend toward decreased medullary enrichment of <italic>Ccr4</italic>-deficient cells may reflect the activity of CCR4 in CD4SP M1 cells (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Medullary accumulation of M1 + M2 CD4SP thymocytes was highly dependent on CCR7, as demonstrated by the significant decrease in medullary accumulation of both <italic>Ccr7<sup>−/−</sup></italic> and DKO cells relative to WT or <italic>Ccr4</italic><sup>−/−</sup> cells (<xref ref-type="fig" rid="fig5">Figure 5B</xref>, <xref ref-type="video" rid="video7">Videos 7</xref> and <xref ref-type="video" rid="video8">8</xref>).</p><media mimetype="video" mime-subtype="mp4" xlink:href="elife-80443-video7.mp4" id="video7"><label>Video 7.</label><caption><title>Two-photon live imaging of WT (red) and <italic>Ccr4<sup>−/−</sup></italic> (blue) FACS sorted CD4SP M1 + M2 thymocyte subsets, migrating in pCX-EGFP thymic slices (green), as shown in <xref ref-type="fig" rid="fig4">Figure 4A</xref>.</title><p>Images were acquired for 15 min at 15-s time intervals through a depth of 40 µm, and maximum intensity projections with and without cell tracks, color coded for elapsed imaging time, are shown side by side.</p></caption></media><media mimetype="video" mime-subtype="mp4" xlink:href="elife-80443-video8.mp4" id="video8"><label>Video 8.</label><caption><title>Two-photon live imaging of DKO (red) and <italic>Ccr7<sup>−/−</sup></italic> (blue) FACS sorted CD4SP M1 + M2 subsets, migrating in pCX-EGFP thymic slices (green).</title><p>Images were acquired for 15 min at 15-s time intervals through a depth of 40 µm, and maximum intensity projections with and without cell tracks, color coded for elapsed imaging time, are shown side by side.</p></caption></media><p>We also considered whether CCR4 and CCR7 alter thymocyte migratory properties. Deficiency in <italic>Ccr4</italic> and/or <italic>Ccr7</italic> did not impact the speed of DP CD3<sup>lo</sup>CD69<sup>+</sup> or CD4SP SM cells. However, CCR7 deficiency resulted in a significant decline in the speed of CD4SP M1 + M2 cells, consistent with our previous finding that CCR7 promotes rapid motility of CD4SP thymocytes (<xref ref-type="bibr" rid="bib26">Ehrlich et al., 2009</xref>). Interestingly, double deficiency of <italic>Ccr4</italic> and <italic>Ccr7</italic> resulted in a significant increase in the average path straightness of all imaged thymocyte subsets (<xref ref-type="fig" rid="fig5">Figure 5E</xref>), suggesting that thymocytes responding to CCR4 and CCR7 ligands migrate in a more tortuous path.</p><p>Overall, CCR4 and CCR7 were required for medullary accumulation of distinct post-positive selection thymocyte subsets, largely consistent with their expression patterns and chemotactic function (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Notably, our results show that CCR4 directs early post-positive selection thymocytes into the medulla, demonstrating that lack of CCR7 expression by post-positive selection thymocytes does not preclude medullary localization. Conversely, expression of CCR7 by CD4SP SM cells does not result in enhanced medullary accumulation over the previous subset. Thus, CCR7 expression on its own is not indicative of robust medullary accumulation. Interestingly, only mature CD4SP M1 + M2 cells accumulate robustly in the medulla and migrate rapidly in a CCR7-dependent manner.</p></sec><sec id="s2-5"><title>CCR4 and CCR7 contribute to early versus late phases of negative selection, respectively</title><p>Given the differential impact of CCR4 versus CCR7 on migration and medullary accumulation of post-positive selection thymocyte subsets, we hypothesized that these chemokine receptors are required for negative selection of early versus late post-positive selection cells, respectively. Consistent with our prior observations (<xref ref-type="bibr" rid="bib33">Hu et al., 2015b</xref>), the frequencies of post-positive selection thymocyte subsets were comparable between littermate control WT and <italic>Ccr4<sup>−/−</sup></italic> mice (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). CD5 expression levels, which are a proxy for self-reactivity (<xref ref-type="bibr" rid="bib8">Azzam et al., 1998</xref>; <xref ref-type="bibr" rid="bib31">Hawiger et al., 2004</xref>; <xref ref-type="bibr" rid="bib62">Persaud et al., 2014</xref>), were also comparable in the absence of <italic>Ccr4</italic> (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). To test the impact of CCR4 and CCR7 on polyclonal negative selection, we quantified the frequency of cleaved-caspase 3<sup>+</sup> thymocytes that had undergone TCR signaling in WT, <italic>Ccr4</italic><sup>−/−</sup>, <italic>Ccr7</italic><sup>−/−</sup>, and DKO mice. Intracellular cleaved-caspase 3 in TCR-signaled thymocytes has been shown to mainly reflect negative selection (<xref ref-type="bibr" rid="bib14">Breed et al., 2019</xref>; <xref ref-type="bibr" rid="bib34">Hu et al., 2016</xref>), although other apoptotic stimuli, such as glucocorticoid hormones, could also induce cleaved-caspase 3 in thymocytes (<xref ref-type="bibr" rid="bib2">Alam et al., 1997</xref>; <xref ref-type="bibr" rid="bib50">Marchetti et al., 2003</xref>). Previous studies showed that negative selection occurs in two main phases, generally defined to occur at the CCR7<sup>−</sup> DP stage in the cortex versus the CCR7<sup>+</sup> CD4SP stage in the medulla (<xref ref-type="bibr" rid="bib14">Breed et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">Daley et al., 2013</xref>; <xref ref-type="bibr" rid="bib34">Hu et al., 2016</xref>; <xref ref-type="bibr" rid="bib69">Stritesky et al., 2013</xref>). Thus, we quantified the impact of <italic>Ccr4</italic> versus <italic>Ccr7</italic> deficiency on ‘early-phase’ and ‘late-phase’ negative selection (<xref ref-type="fig" rid="fig6">Figure 6A, B</xref>). Interestingly, the majority of early-phase DP cells undergoing negative selection expressed only CCR4, as did ~60% of late-phase CD4SP cells; thus, the majority of thymocytes undergoing clonal deletion express CCR4, but not CCR7. CCR7 was expressed by ~40% CD4SP and 60% of CD8SP cells undergoing negative selection (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). The frequency of total thymocytes undergoing negative selection declined significantly only in DKO mice (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). However, CCR4 deficiency resulted in a significant decrease in the frequency of thymocytes undergoing early-phase, but not late-phase negative selection (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). In contrast, CCR7 deficiency resulted in a significantly lower frequency of thymocytes undergoing late-phase negative selection, with no impact on early-phase negative selection. Double deficiency for CCR4 and CCR7 significantly diminished both early- and late-phase negative selection (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). It was reported that most negative selection occurs at the earlier phase (<xref ref-type="bibr" rid="bib14">Breed et al., 2019</xref>; <xref ref-type="bibr" rid="bib69">Stritesky et al., 2013</xref>), which is consistent with the 2:1 ratio of WT thymocytes undergoing early- to late-phase negative selection (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). This ratio falls significantly in <italic>Ccr4</italic><sup>−/−</sup> mice and increases significantly in <italic>Ccr7</italic><sup>−/−</sup> and DKO mice, highlighting the respective contributions of CCR4 and CCR7 to early versus late phases of negative selection, respectively (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). Altogether, these data indicate that, consistent with its role in promoting medullary entry of early-post-positive selection thymocytes, CCR4 is required for efficient early-phase negative selection of polyclonal DP cells. In contrast, CCR7, which promotes medullary accumulation of more mature CD4SP and CD8SP cells, is required for efficient negative selection of late-phase CD4SP and CD8SP cells.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>CCR4 and CCR7 contribute to early versus late phases of negative selection, respectively.</title><p>(<bold>A</bold>) Flow cytometric gating scheme to quantify thymocytes undergoing early-phase (DP) or late-phase (CD4SP + CD8SP) negative selection. Representative data from a WT mouse are shown. (<bold>B</bold>) Representative flow cytometry plots showing CCR4 and CCR7 expression by thymocytes undergoing early- and late-phase negative selection, as gated in (<bold>A</bold>). (<bold>C</bold>) Frequencies of total, early-phase (DP), and late-phase (CD4SP + CD8SP) negative selection among all live thymocytes in WT, <italic>Ccr4<sup>−/−</sup></italic>, <italic>Ccr7<sup>−/−</sup></italic>, and DKO mice. (<bold>D</bold>) Ratio of thymocytes undergoing early- to late-phase negative selection in WT, <italic>Ccr4<sup>−/−</sup></italic>, <italic>Ccr7<sup>−/−</sup></italic>, and DKO mice. For (<bold>C</bold>) and (<bold>D</bold>), one-way ANOVA with Dunnett’s multiple comparisons correction was used for statistical analysis (mean ± SEM; <italic>N</italic> = 22 for WT, <italic>N</italic> = 20 for <italic>Ccr4<sup>−/−</sup></italic>, <italic>N</italic> = 14 for <italic>Ccr7<sup>−/−</sup></italic>, <italic>N</italic> = 24 for DKO; *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80443-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Thymocyte composition and CD5 levels are not altered in <italic>Ccr4<sup>−/−</sup></italic> mice.</title><p>(<bold>A</bold>) Thymocyte subset frequencies in littermate WT and <italic>Ccr4<sup>−/−</sup></italic> mice. (<bold>B</bold>) CD5 expression levels on the indicated thymocyte subsets from littermate WT and <italic>Ccr4<sup>−/−</sup></italic> mice, normalized to the DP CD3<sup>−</sup>CD69<sup>−</sup> subset of each mouse. For (<bold>A</bold>) and (<bold>B</bold>), data were compiled from six independent experiments and significance determined using unpaired <italic>t</italic>-tests with Holm–Šídák’s multiple comparisons correction (mean ± SEM; <italic>N</italic> = 13 for WT, <italic>N</italic> = 18 for <italic>Ccr4<sup>−/−</sup></italic>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80443-fig6-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-6"><title>CCR4 and CCR7 suppress autoinflammation in distinct tissues, with CCR4 promoting tolerance to activated APCs</title><p>Given that CCR4 and CCR7 enforced central tolerance at distinct stages of T cell development when thymocytes might interact with different APCs, these chemokine receptors could promote tolerance to distinct self-antigens. To evaluate this possibility, we assessed the presence of spontaneous autoimmunity/autoinflammation in multiple organs of WT, <italic>Ccr4<sup>−/−</sup></italic>, <italic>Ccr7<sup>−/−</sup></italic>, and DKO mice. We previously found that <italic>Ccr4<sup>−/−</sup></italic> and <italic>Ccr7<sup>−/−</sup></italic> mice had anti-nuclear autoantibodies by ~12 months of age (<xref ref-type="bibr" rid="bib33">Hu et al., 2015b</xref>). Here, we detected anti-nuclear autoantibodies in the serum of 67% of <italic>Ccr4<sup>−/−</sup></italic>, 100% of <italic>Ccr7<sup>−/−</sup></italic>, and 75% of DKO <italic>mice</italic> between 5 and 6.5 months of age, relative to 22% of WT mice (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>). Thus, we evaluated other organs from mice in this age range for lymphocytic infiltrates or inflammation. Colon inflammation was not observed in <italic>Ccr7</italic><sup>−/−</sup> or WT mice. Colons from <italic>Ccr4</italic><sup>−/−</sup> mice showed mild epithelial hyperplasia, with small foci of acute inflammation. In contrast, DKO mice demonstrated moderate to severe colonic mucosal hyperplasia, with abundant acute and chronic inflammation extending into the submucosa. Active ulcerations were observed in 40% of DKO mice, with crypt abscesses and regenerative changes consistent with prior ulceration in most DKO mice (<xref ref-type="fig" rid="fig7">Figure 7A</xref>, left). Histologic scores were markedly and significantly higher in DKO mice compared to WT, with a trend toward higher scores in <italic>Ccr4<sup>−/−</sup></italic> mice that is absent in <italic>Ccr7<sup>−/−</sup></italic> mice (<xref ref-type="fig" rid="fig7">Figure 7A</xref>, right), suggesting that CCR4 and CCR7 collaboratively maintain self-tolerance in the colon (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Immune infiltrates were elevated in the liver, lacrimal glands, and submandibular glands of <italic>Ccr7<sup>−/−</sup></italic> and DKO mice, but not <italic>Ccr4<sup>−/−</sup></italic> mice at 6 months of age (<xref ref-type="fig" rid="fig7">Figure 7B</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B–D</xref>), indicating that CCR7 plays a dominant role in promoting tolerance to endocrine organs, consistent with the established requirement for CCR7 to mediate negative selection against mTEC-expressed TRAs, but not ubiquitous self-antigens (<xref ref-type="bibr" rid="bib59">Nitta et al., 2009</xref>). Interestingly, 70–75% of <italic>Ccr4</italic><sup>−/−</sup> mice, compared to 17–20% of WT and 0% of <italic>Ccr7</italic><sup>−/−</sup> mice displayed moderate lymphoid hyperplasia in the spleen and mesenteric lymph nodes of 12-month-old mice (<xref ref-type="fig" rid="fig7">Figure 7C</xref>, right). Immunofluorescent staining of lymph nodes from 6-month-old <italic>Ccr4</italic><sup>−/−</sup> mice revealed abnormal CD4 and CD8 distributions/expansions in T cell zones relative to WT mice (<xref ref-type="fig" rid="fig7">Figure 7C</xref>, left). As expected, T cell zones from <italic>Ccr7<sup>−/−</sup></italic> mice were hypoplastic (not shown), reflecting the role of CCR7 in mediating T cell entry into lymph nodes (LNs). These results indicate that CCR4 maintains T cell homeostasis in secondary lymphoid organs.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>CCR4 and CCR7 promote tolerance to distinct organs, with CCR4 promoting tolerance to activated antigen-presenting cells.</title><p>(<bold>A</bold>) Representative images of H&amp;E stains from the colon of 5- to 6-month-old WT, <italic>Ccr4<sup>−/−</sup></italic>, <italic>Ccr7<sup>−/−</sup></italic>, or DKO mice (left). Bars, 200 µm. Histological lesion score was quantified by a pathologist blinded to genotype (right). One-way ANOVA was used to determine significance between groups (mean ± SEM; ***p &lt; 0.001). (<bold>B</bold>) Representative images of H&amp;E stains from extraorbital lacrimal glands of 5- to 6-month-old WT, <italic>Ccr4<sup>−/−</sup></italic>, <italic>Ccr7<sup>−/−</sup></italic>, or DKO mice (left). Bars, 500 µm. Arrows indicate lymphocytic infiltrate foci. The number of infiltrate foci per 10 mm<sup>2</sup> was quantified (right), and one-way ANOVA was used to test significance between groups (mean ± SEM; *p &lt; 0.05, ***p &gt; 0.001). (<bold>C</bold>) Representative immunofluorescent images of CD4 (green), CD8 (red), and B220 (blue) on cryosections of inguinal lymph nodes from 5- to 6-month-old WT and <italic>Ccr4</italic><sup>−/−</sup> mice (left). Frequency of moderate lymphoid hyperplasia in mLNs and spleens from 12- to 13-month-old WT, <italic>Ccr4<sup>−/−</sup></italic>, and <italic>Ccr7<sup>−/−</sup></italic> mice, as determined by a veterinary pathologist, blinded to genotype (right). Fisher’s exact test was used to determine significance. Bars, 300µm. Expression of CCR4 ligands (<bold>D</bold>) and CCR7 ligands (<bold>E</bold>) by distinct thymic antigen-presenting cell subsets, assessed by quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Expression levels were normalized to subsets previously reported to express the respective ligands: CCL17 and CCL22 expression were normalized to cDC2 (<xref ref-type="bibr" rid="bib33">Hu et al., 2015b</xref>), and CCL19 and CCL21 expression to mTEC<sup>lo</sup> (<xref ref-type="bibr" rid="bib37">Ki et al., 2014</xref>; <xref ref-type="bibr" rid="bib56">Misslitz et al., 2004</xref>). Data were compiled from three independent experiments with triplicates. One-way ANOVA with Dunnett’s multiple comparisons correction was used for statistical analysis (mean ± SEM; ns: p &gt; 0.05, **p &lt; 0.01). (<bold>F</bold>) The percentage of WT or <italic>Ccr4<sup>−/−</sup></italic> T cells that proliferated at days 3 and 5 when cultured without splenocytes, with unstimulated splenocytes, or with lipopolysaccharide (LPS)-stimulated splenocytes, as indicated. Data were compiled from four independent experiments with triplicate wells, and unpaired <italic>t</italic>-tests with Holm–Šídák’s multiple comparisons correction was used for statistical analysis (mean ± SEM; *p &lt; 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80443-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>CCR4 and CCR7 support self-tolerance in different organs.</title><p>(<bold>A</bold>) Representative images of Rag2<sup>−/−</sup> kidney sections immunostained with serum from 5- to 6.5-month-old <italic>WT</italic>, <italic>Ccr4<sup>−/−</sup></italic>, <italic>Ccr7<sup>−/−</sup></italic>, or DKO mice (left). Anti-nuclear autoantibodies were detected as an overlay of anti-mouse IgG (red) and a nuclear stain (blue). Proportion of mice containing anti-nuclear serum autoantibodies was quantified (right). Fisher’s exact test was used to determine significance between groups (**p &lt; 0.01).Bars, 200 µm. (<bold>B</bold>) Representative images of H&amp;E stains from the liver of 5- to 6-month-old <italic>WT</italic>, <italic>Ccr4<sup>−/−</sup></italic>, <italic>Ccr7<sup>−/−</sup></italic>, and DKO mice (left). Bars, 500 µm. Histological lesion score was quantified by a veterinary pathologist (right). One-way analysis of variance (ANOVA) was used to test significance between groups (mean ± standard error of the mean [SEM]; **p &gt; 0.01). Representative images of H&amp;E stains from intraorbital lacrimal glands (<bold>C</bold>) and submandibular salivary glands (<bold>D</bold>) of 5- to 6-month-old <italic>WT</italic>, <italic>Ccr4<sup>−/−</sup></italic>, <italic>Ccr7<sup>−/−</sup>,</italic> or DKO mice (left). Bars, 500 µm. Arrows indicate lymphocytic infiltrate foci. The number of infiltrate foci per 10 mm<sup>2</sup> was quantified (right). One-way ANOVA was used to determine the significant differences between groups (mean ± SEM; *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80443-fig7-figsupp1-v2.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>CCR4 promotes tolerance to activated antigen-presenting cells (APCs).</title><p>(<bold>A</bold>) Gating scheme for FACS sorting of thymic APC subsets analyzed by qRT-PCR for expression of CCR4 and CCR7 ligands. (<bold>B</bold>) Surface expression of MHC-II, CD80, and CD86 on APC subsets from unstimulated or toll-like receptor (TLR) ligand-stimulated splenocytes used in the proliferation assays in <xref ref-type="fig" rid="fig7">Figure 7F</xref>. Individual data points represent the GMFI of the indicated markers on each respective APC subset. Data were compiled from five individual experiments. One-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons correction was used for statistical analysis (mean ± SEM; **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001). (<bold>C</bold>) The percentage of WT and <italic>Ccr4<sup>−/−</sup></italic> T cells that proliferated at days 3 and 5 when cultured with high molecular weight (HMW) poly(I:C), low molecular weight (LMW) poly(I:C), or ODN1826 (CpG)-stimulated splenocytes. Data were compiled from three to four independent experiments with triplicate wells, and unpaired <italic>t</italic>-tests with Holm–Šídák’s multiple comparisons correction was used for statistical analysis (mean ± SEM).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80443-fig7-figsupp2-v2.tif"/></fig></fig-group><p>Given the distinct contributions of CCR4 and CCR7 to establishment of central tolerance and maintenance of self-tolerance across different organs, we considered the possibility that CCR4 and CCR7 might promote thymocyte selection against antigens presented by different types of thymic APCs. Thymic APC subsets were FACS purified (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2A</xref>), and expression of CCR4 and CCR7 ligands was quantified by qRT-PCR. Consistent with our previous study (<xref ref-type="bibr" rid="bib33">Hu et al., 2015b</xref>), the CCR4 ligands CCL17 and CCL22 were expressed by Sirpα<sup>+</sup> cDC2 cells. Activated thymic CCR7<sup>+</sup> cDCs (<xref ref-type="bibr" rid="bib5">Ardouin et al., 2016</xref>; <xref ref-type="bibr" rid="bib35">Hu et al., 2017</xref>; <xref ref-type="bibr" rid="bib60">Oh et al., 2018</xref>) also expressed CCR4 ligands, with the highest levels of CCL22 expressed by activated DCs (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). Thymic B cells also expressed CCL22, consistent with a recent report that CCL22 expressed by activated B cells promotes interactions with T cells in the germinal center (<xref ref-type="bibr" rid="bib48">Liu et al., 2021</xref>). The CCR7 ligands CCL19 and CCL21 were expressed by mTEC subsets, with the highest levels of CCL21 expression by mTEC<sup>lo</sup> cells (<xref ref-type="fig" rid="fig7">Figure 7E</xref>), consistent with previous reports (<xref ref-type="bibr" rid="bib12">Bornstein et al., 2018</xref>; <xref ref-type="bibr" rid="bib41">Kozai et al., 2017</xref>). These results suggest that CCR4 may promote thymocyte interactions with B cells and cDCs, including activated CCR7<sup>+</sup> cDCs that express elevated levels of MHC-II and co-stimulatory molecules (<xref ref-type="bibr" rid="bib5">Ardouin et al., 2016</xref>; <xref ref-type="bibr" rid="bib35">Hu et al., 2017</xref>), while CCR7 may promote thymocyte interactions primarily with mTECs.</p><p>Because a large proportion of thymic B cells (<xref ref-type="bibr" rid="bib20">Cepeda et al., 2018</xref>) and cDCs (<xref ref-type="bibr" rid="bib5">Ardouin et al., 2016</xref>; <xref ref-type="bibr" rid="bib35">Hu et al., 2017</xref>) have activated phenotypes, and T cell zones in the lymph nodes of <italic>Ccr4<sup>−/−</sup></italic> mice are hyperplastic (<xref ref-type="fig" rid="fig7">Figure 7C</xref>), we considered the possibility that CCR4-directed negative selection could facilitate establishment of central tolerance to antigens expressed by activated APCs. To explore this hypothesis, CD45.1<sup>+</sup> congenic splenocytes were stimulated overnight with toll-like receptor (TLR) ligands. We confirmed that stimulation with TLR ligands induced activation of the splenic cDCs and B cells based on upregulation of MHC-II, CD80, and CD86 (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2B</xref>). The activated splenocytes were then co-cultured with CD45.2<sup>+</sup> CD4<sup>+</sup> conventional T cells isolated from WT or <italic>Ccr4<sup>−/−</sup></italic> spleens, and the frequency of T cells induced to proliferate was quantified after 3–5 days (<xref ref-type="fig" rid="fig7">Figure 7F</xref>). Notably, LPS-stimulated splenocytes induced more proliferation of <italic>Ccr4<sup>−/−</sup></italic> versus WT CD4<sup>+</sup> T cells at days 3 and 5 (<xref ref-type="fig" rid="fig7">Figure 7G</xref>). Splenocytes that were unstimulated or activated by other TLR ligands did not preferentially induce <italic>Ccr4</italic><sup>−/−</sup> T cell proliferation (<xref ref-type="fig" rid="fig7">Figure 7E</xref>; <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2C</xref>). Taken together, these data suggest that CCR4 promotes thymocyte central tolerance to self-antigens expressed by LPS-activated APCs, possibly by promoting interactions with such APCs in the thymus.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Our data demonstrate that CCR4 and CCR7 play distinct roles in thymocyte localization and the induction of T cell central tolerance. We find that CCR4 is upregulated by thymocytes within a few hours of the initiation of positive selection, largely coincident with the timing of medullary entry. CCR4 is expressed by almost all early post-positive selection DP CD3<sup>lo</sup>CD69<sup>+</sup> cells and is required for their twofold accumulation in the medulla and efficient negative selection. Notably, the majority of thymocytes undergoing negative selection are DP CD3<sup>lo</sup>CD69<sup>+</sup> cells, which do not express CCR7. Thus, while the role of CCR4 in negative selection has been questioned (<xref ref-type="bibr" rid="bib22">Cowan et al., 2014</xref>), our analyses reveal an important role for this chemokine receptor in localization and central tolerance of early post-positive selection polyclonal thymocytes, in keeping with medullary localization of the CCR4 ligand CCL22. In contrast, our study and a previous report (<xref ref-type="bibr" rid="bib49">Lutes et al., 2021</xref>) show that CCR7 is not upregulated until 48–72 hr after positive selection. CCR7 is expressed by about half of the CD4SP SM cells, which continue to express CCR4 and respond to CCR4 ligands. In keeping with dual expression, CCR4 and CCR7 cooperate to induce the twofold accumulation of CD4SP SM cells in the medulla. As thymocytes mature further to the CD4SP and CD8SP M1 and M2 stages, CCR7 is upregulated, CCR4 is downregulated, and the cells become increasingly chemotactic to CCR7 ligands. We find that CCR7 is required for the robust accumulation of CD4SP M1 + M2 cells in the medulla and for late-phase negative selection of CD4SP and CD8SP thymocytes. The finding that the overall frequency of negative selection in the thymus is reduced significantly only in the absence of both CCR4 and CCR7 further indicates that these chemokine receptors both contribute to the induction of central tolerance. Altogether, our findings show a temporally correlated shift after positive selection from a requirement for CCR4 to a requirement for CCR7 for thymocyte medullary localization and negative selection.</p><p>Several of our findings raise questions about the current model of negative selection, which assumes that CCR7 expression is a surrogate indicator of thymocyte medullary versus cortical localization (<xref ref-type="bibr" rid="bib14">Breed et al., 2019</xref>; <xref ref-type="bibr" rid="bib34">Hu et al., 2016</xref>). This assumption is based on studies, including our own, showing that CCR7 is expressed by CD4SP and CD8SP thymocytes, which are localized mainly within the thymic medulla at steady state, as evidenced by immunostaining (<xref ref-type="bibr" rid="bib27">Ehrlich, 2016</xref>). In addition, prior studies showed that accumulation of CD4SP cells in the medulla is CCR7 dependent (<xref ref-type="bibr" rid="bib26">Ehrlich et al., 2009</xref>; <xref ref-type="bibr" rid="bib71">Ueno et al., 2004</xref>). Consistent with these findings, we confirm that robust medullary accumulation of the more mature CD4SP M1 and M2 cells is CCR7 dependent. Equating CCR7 expression with medullary localization has led to a model in which the early phase of negative selection is thought to impact CCR7<sup>−</sup> DP cells in the cortex, while the later phase impacts more mature CCR7<sup>+</sup> cells in the medulla (<xref ref-type="bibr" rid="bib14">Breed et al., 2019</xref>; <xref ref-type="bibr" rid="bib34">Hu et al., 2016</xref>). In support of cortical negative selection, apoptotic TCR transgenic cells were located in the cortex of the H-Y<sup>CD4</sup> model of negative selection (<xref ref-type="bibr" rid="bib53">McCaughtry et al., 2008</xref>). Also, TCR-signaled thymocytes are present at the cortical side of the CMJ in <italic>Bim</italic><sup>−/−</sup> mice, in which apoptosis following strong TCR signaling is impaired (<xref ref-type="bibr" rid="bib69">Stritesky et al., 2013</xref>), suggesting thymocytes encounter negatively selecting self-antigens in the cortex. Furthermore, CCR7 deficiency impairs negative selection to TRAs, but not to ubiquitous self-antigens (<xref ref-type="bibr" rid="bib43">Kurobe et al., 2006</xref>; <xref ref-type="bibr" rid="bib59">Nitta et al., 2009</xref>), indicating that CCR7<sup>+</sup> mature thymocytes undergo negative selection in the medulla, where TRAs are expressed by mTECs.</p><p>While our data confirm that CCR7 is critical for medullary accumulation of more mature thymocyte subsets, we find that CCR7 expression is not a reliable indicator of medullary localization in earlier post-positive selection thymocytes. CCR7<sup>−</sup> DP CD3<sup>lo</sup>CD69<sup>+</sup> enter the medulla, where they accumulate in a CCR4-dependent manner with a twofold higher density than in the cortex, so CCR7 is not required for medullary entry. Conversely, although almost half of CD4SP SM cells express CCR7, their medullary: cortical density is also twofold. CCR7 deficiency only modestly diminished medullary accumulation of CD4SP SM cells, consistent with their moderate chemotaxis toward CCR7 ligands; instead, CCR4 played a greater role in medullary accumulation of this subset. Thus, the two earliest post-positive selection subsets accumulate in the medulla at similar densities, despite CCR7 upregulation by one of these subsets. DP CD3<sup>lo</sup>CD69<sup>+</sup> and CD4SP SM cells both migrate in the cortex and in the medulla and could thus encounter APCs presenting cognate self-antigens that drive negative selection in either region. Based on the twofold enrichment of DP CD3<sup>lo</sup>CD69<sup>+</sup> cells in the medulla, a substantial proportion of CCR7<sup>−</sup> early-phase negative selection may occur in the medulla. Moreover, some late-phase negative selection, defined by either CCR7 expression or maturation to the CD4SP SM stage, may occur in the cortex. These data indicate that CCR7 expression cannot be used as a reliable surrogate biomarker of medullary localization. The location in which thymocytes undergo negative selection impacts which APC subsets will be encountered, altering the spectrum of self-antigens to which thymocytes are tolerized. Thus, it will be important to determine where distinct thymocyte subsets undergo negative selection and which APCs promote tolerance of these different subsets.</p><p>It has recently been suggested that CXCR4 expression must be extinguished after positive selection to release thymocytes from binding to cTECs in the cortex, thus enabling medullary entry (<xref ref-type="bibr" rid="bib36">Kadakia et al., 2019</xref>). However, we found that while CXCR4 is partially downregulated on the cell surface of post-positive selection thymocytes, all subsets except CD4SP SM and DP CD3<sup>+</sup> CD69<sup>+</sup> cells undergo chemotaxis to CXCL12, despite their accumulation in the medulla. These findings indicate that CXCR4 expression and activity are compatible with medullary localization. This seeming discrepancy may reflect the overexpression system used to reveal that persistent CXCR4 expression prevented thymocyte medullary entry, perhaps resulting in superphysiological tethering of cells to the cortex (<xref ref-type="bibr" rid="bib36">Kadakia et al., 2019</xref>). In keeping with the ability of CXCR4<sup>+</sup> thymocytes to enter the medulla, higher CXCR4 surface expression and responsiveness are observed in mature CD4SP and CD8SP M1 and M2 subsets, which accumulate in the medulla to the greatest extent. It is notable that chemotactic activity of CXCR4 is completely extinguished at the CD4SP SM stage, despite continued CXCR4 expression, but not at the more mature CD4SP and CD8SP stages, suggesting a thymocyte-intrinsic mechanism of diminished responsiveness to CXCR4, similar to the lack of responsiveness to CCR7 ligands by this subset. It is possible that the lack of CXCR4 activity in CD4SP SM cells may permit medullary entry, consistent with the need to release post-positive selection thymocytes from binding to cTECs (<xref ref-type="bibr" rid="bib36">Kadakia et al., 2019</xref>); however, DP CD3<sup>lo</sup>CD69<sup>+</sup> cells enter the medulla just as efficiently as CD4SP SM cells despite continued CXCR4 responsiveness, suggesting factors other than reduced CXCR4 activity likely enable medullary entry. The role for increased CXCR4 activity in more mature SP thymocytes remains to be determined but could impact thymocyte egress. Identifying intrinsic regulators of chemokine receptor responsiveness in different thymocyte subsets will further our understanding of the complex mechanisms underlying the orchestration of thymocyte movement and selection in the thymus.</p><p>A major outstanding question raised by our findings is whether the combinatorial and temporally regulated changes in chemokine receptor expression on post-positive selection thymocytes drive interactions with distinct APC subsets. Here we show that CCR7 ligands are expressed by mTECs, while CCR4 ligands are expressed mainly by cDC2s and activated cDCs, with some expression by thymic B cells. Thus, CCR7 activity may drive interactions with mTECs, possibly explaining why CCR7 is particularly required for negative selection to TRAs, consistent with the finding that CCR7 deficiency results in autoimmune infiltrates in endocrine organs, as occurs in Aire-deficient mice (<xref ref-type="bibr" rid="bib3">Anderson et al., 2002</xref>; <xref ref-type="bibr" rid="bib43">Kurobe et al., 2006</xref>; <xref ref-type="bibr" rid="bib59">Nitta et al., 2009</xref>). In contrast, CCR4 activity may promote interactions with and tolerance to cDC2s, B cells, and activated cDCs, consistent with our finding that <italic>Ccr4</italic><sup>−/−</sup> mice showed T cell hyperplasia in secondary lymphoid organs and that <italic>Ccr4</italic><sup>−/−</sup> T cells undergo increased proliferation to LPS-activated splenic APCs. Recently, a subset of cDC2s has been shown to present circulating antigens to induce negative selection, and another subset has been shown to traffic microbial antigens to the thymus, impacting thymocyte selection (<xref ref-type="bibr" rid="bib6">Atibalentja et al., 2009</xref>; <xref ref-type="bibr" rid="bib72">Vollmann et al., 2021</xref>; <xref ref-type="bibr" rid="bib76">Zegarra-Ruiz et al., 2021</xref>). B cells also present self-antigens to induce thymocyte negative selection (<xref ref-type="bibr" rid="bib61">Perera et al., 2016</xref>; <xref ref-type="bibr" rid="bib75">Yamano et al., 2015</xref>). While we find CCL22 is expressed predominantly in the medulla, and CCR4 promotes medullary accumulation of early-post-positive selection DPs, our study does not rule out the possibility that CCR4 could also enforce interactions between CCR4-responsive thymocytes and cortical DCs expressing CCL22, which could contribute to cortical negative selection. This possibility is particularly intriguing in light of the fact that DP CD3<sup>lo</sup>CD69<sup>+</sup> and CD4SP SM cells respond to CCR4 ligands and migrate both in the cortex and medulla. The finding that CCR4 and CCR7 cooperate to prevent inflammation in the colon is unexpected and warrants further exploration. Whether the inflammatory phenotypes observed reflect impaired central tolerance due to diminished interactions between thymocytes and distinct thymic APCs and/or impaired peripheral tolerance remains to be determined.</p><p>Altogether, our findings suggest a layered process of central-tolerance induction in which CCR4 first promotes interactions with DCs and B cells, driving self-tolerance to activated APCs, which may be present in both the cortex and/or medulla. As thymocytes mature further, CCR7 is expressed and becomes active, drawing the cells robustly into the medulla, where the partially tolerized repertoire can be focused on tolerance induction to the sparse TRAs. One limitation of our current system is that ex vivo live thymic slices are not equivalent to in situ thymi, as they lack circulation, for example. We note, however, that short-term live thymic slice cultures have been widely used to investigate the development, localization, migration, and positive and negative selection of thymocytes, as they have been shown to faithfully reflect these in vivo processes, including confirming that CCR7 signaling induces chemotaxis of mature thymocytes from the cortex into the medulla (<xref ref-type="bibr" rid="bib7">Au-Yeung et al., 2014</xref>; <xref ref-type="bibr" rid="bib25">Dzhagalov et al., 2013</xref>; <xref ref-type="bibr" rid="bib26">Ehrlich et al., 2009</xref>; <xref ref-type="bibr" rid="bib46">Lancaster et al., 2019</xref>; <xref ref-type="bibr" rid="bib54">Melichar et al., 2013</xref>; <xref ref-type="bibr" rid="bib64">Ross et al., 2014</xref>). Because our study measured differences in medullary accumulation of thymocytes that differed genetically only in expression of CCR4 and/or CCR7, we attribute altered localization to the impact of these chemokine receptors on thymocyte migration. However, we note the possibility that CCR4 and CCR7 could signal in conjunction with survival cues, like cytokines, localized to different thymic microenvironments, which could also impact survival of thymocytes in different regions. As thymocytes were imaged within a few hours of entering slices, differential survival in the cortex and medulla due to cytokine cues is somewhat less likely than differential migration. Multiple aspects of our revised model of thymocyte migration and central tolerance, including the impact of CCR4 and CCR7 on interactions with distinct APCs during tolerance induction and on selection of distinct TCR clones will be tested in future studies.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Reagent type (species) or resource</th><th align="left" valign="top">Designation</th><th align="left" valign="top">Source or reference</th><th align="left" valign="top">Identifiers</th><th align="left" valign="top">Additional information</th></tr></thead><tbody><tr><td align="left" valign="top">gene (<italic>Mus musculus</italic>)</td><td align="left" valign="top">Ccr4</td><td align="left" valign="top">GenBank</td><td align="left" valign="top">Gene ID: 12773</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">gene (<italic>Mus musculus</italic>)</td><td align="left" valign="top">Ccr7</td><td align="left" valign="top">GenBank</td><td align="left" valign="top">Gene ID: 12775</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="top">C57BL6/J</td><td align="left" valign="top">Jackson Laboratory</td><td align="left" valign="top">Strain #: 000664</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="top">B6.SJL-Ptprc<sup>a</sup> PepC<sup>b</sup>/BoyJ (CD45.1)</td><td align="left" valign="top">Jackson Laboratory</td><td align="left" valign="top">Strain #: 002014</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="top">C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-I)</td><td align="left" valign="top">Jackson Laboratory</td><td align="left" valign="top">Strain #: 003831</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="top">B6.Cg-Tg(TcraTcrb)425Cbn/J (OT-II)</td><td align="left" valign="top">Jackson Laboratory</td><td align="left" valign="top">Strain #: 004194</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="top">B6(Cg)-Rag2<sup>tm1.1Cgn</sup>/J (Rag2<sup>-/-</sup>)</td><td align="left" valign="top">Jackson Laboratory</td><td align="left" valign="top">Strain #: 008449</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="top">B6.129P2(C)Ccr7<sup>tm1Rfo</sup>r/J (Ccr7<sup>-/-</sup>)</td><td align="left" valign="top">Jackson Laboratory</td><td align="left" valign="top">Strain #: 006621</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="top">B6.129S2-H2<sup>dlAb1-Ea</sup>/J (H2<sup>-/-</sup>)</td><td align="left" valign="top">Jackson Laboratory</td><td align="left" valign="top">Strain #: 003584</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="top">B6.129P2-B2m<sup>tm1Unc</sup>/DcrJ (B2m<sup>-/-</sup>)</td><td align="left" valign="top">Jackson Laboratory</td><td align="left" valign="top">Strain #: 002087</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="top">C57BL/6-Tg(Nr4a1-EGFP/cre)820Khog/J (Nr4a1<sup>GFP</sup>)</td><td align="left" valign="top">Jackson Laboratory</td><td align="left" valign="top">Strain #: 016617</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="top">Ccr4<sup>-/-</sup></td><td align="left" valign="top"><xref ref-type="bibr" rid="bib21">Chvatchko et al., 2000</xref></td><td align="left" valign="top"/><td align="left" valign="top">Generously provided by A.D. Luster (Massachusetts General Hospital, Boston, MA)</td></tr><tr><td align="left" valign="top">genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="top">pCX-EGFP</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib73">Wright et al., 2001</xref></td><td align="left" valign="top"/><td align="left" valign="top">Generously provided by Irving L. Weissman (Stanford University, Stanford, CA)</td></tr><tr><td align="left" valign="top">genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="top">Rag2p-GFP</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib13">Boursalian et al., 2004</xref></td><td align="left" valign="top"/><td align="left" valign="top">Generously provided by Ellen R. Richie (the University of Texas MD Anderson Center, Houston, TX)</td></tr><tr><td align="left" valign="top">genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="top">Ccr4<sup>-/-</sup>; Ccr7<sup>-/-</sup>(DKO)</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">See Materials and Methods, Section “Mice”</td></tr><tr><td align="left" valign="top">genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="top">OT-I Rag2<sup>-/-</sup></td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">See Materials and Methods, Section “Mice”</td></tr><tr><td align="left" valign="top">genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="top">OT-II Rag2<sup>-/-</sup> H2<sup>-/-</sup></td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">See Materials and Methods, Section “Mice”</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">PE/Cyanine 7 Anti-mouse CD3, Rat Monoclonal, clone 17 A2</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 100220; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1732057">AB_1732057</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">PE Anti-mouse CCR4, Armenian Hamster Monoclonal, clone 2 G12</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 131204; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1236367">AB_1236367</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">APC Anti-mouse CCR7, Rat Monoclonal, clone 4B12</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 120108; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_389234">AB_389234</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">Brilliant Violet 510 Anti-mouse CD4, Rat Monoclonal, clone RM4-5</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 100559; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2562608">AB_2562608</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">PE/Cyanine7 Anti-mouse CD5, Rat Monoclonal, clone 53–7.3</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 100622; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2562773">AB_2562773</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">FITC Anti-mouse CD8a, Rat Monoclonal, clone 53–6.7</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 100706; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312745">AB_312745</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">Alexa Flour 700 Anti-mouse CD11b, Rat Monoclonal, clone M1/70</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 101222; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_493705">AB_493705</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">Pacific Blue Anti-mouse CD11c, Armenian Hamster Monoclonal, clone N418</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 117322; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_755988">AB_755988</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">PerCP/Cyanine5.5 Anti-mouse CD19, Rat Monoclonal, clone 1D3/CD19</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 152405; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2629814">AB_2629814</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">APC Anti-mouse CD25, Rat Monoclonal, clone PC61</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 102012; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312861">AB_312861</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">APC Anti-mouse CD45.1, Mouse (A. SW) monoclonal, clone A20</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 110714; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313503">AB_313503</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">PE Anti-mouse CD45.2, Mouse (SJL) monoclonal, clone 104</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 109808; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313445">AB_313445</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">Biotin Anti-mouse CD69, Armenian Hamster monoclonal, clone H1.2F3</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 104504; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313107">AB_313107</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">Brilliant Violet 510 Anti-mouse CD90.2, Rat monoclonal, clone 30 H12</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 105335; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2566587">AB_2566587</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">PE/Dazzle 594 Anti-mouse CXCR4, Rat monoclonal, clone L276F12</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 146514; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2563683">AB_2563683</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">Alexa Flour 488 Anti-mouse Cleaved Caspase 3 (Asp175), Rabbit polyclonal</td><td align="left" valign="top">Cell Signaling Technology</td><td align="left" valign="top">Cat # 9669 S</td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">PE Anti-mouse EpCAM, Rat monoclonal, clone G8.8</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 118206; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1134172">AB_1134172</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">APC/Cyanine7 Anti-mouse F4/80, Rat monoclonal, clone BM8</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 123118; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_893477">AB_893477</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">PE/Cyanine5 Anti-mouse Gr1, Rat monoclonal, clone RB6-8C5</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 108410; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313375">AB_313375</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">PerCP/Cyanine5.5 Anti-mouse H-2Kb (MHCI), Mouse (BALB/c) monoclonal, clone AF6-88.5</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 116516; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1967133">AB_1967133</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">PE/Cyanine7 Anti-mouse I-A/I-E (MHCII), Rat Monoclonal, clone M5/114.15.2</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 107630; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2069376">AB_2069376</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">Alexa Flour 488 Anti-mouse PDCA1, Rat Monoclonal, clone 927</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 127012; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1953287">AB_1953287</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">PE/Cyanine5 Anti-mouse Ter-119, Rat monoclonal, clone TER-119</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 116209; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313710">AB_313710</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">APC Anti-mouse Sirpα, Rat monoclonal, clone P84</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 144014; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2564061">AB_2564061</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">Brilliant Violet 650Anti-mouse XCR1, mouse monoclonal, clone ZET</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 148220; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2566410">AB_2566410</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">Biotin Anti-mouse CD11c, Armenian Hamster monoclonal, clone N418</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 117303; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313772">AB_313772</ext-link></td><td align="char" char="." valign="top">(1:50)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">APC Anti-mouse CD4, Rat monoclonal, clone GK1.5</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 100412; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312696">AB_312696</ext-link></td><td align="char" char="." valign="top">(1:100)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">APC Anti-mouse CD31, Rat monoclonal, clone 390</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat# 102410; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312905">AB_312905</ext-link></td><td align="char" char="." valign="top">(1:100)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">Biotin anti-mouse/human CD45R/B220, Rat monoclonal, clone RA3-6B2</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat # 103204; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312989">AB_312989</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">Purified Rat anti-mouse B220, Rat monoclonal, clone RA3.3A1/6.1</td><td align="left" valign="top">BioXCell</td><td align="left" valign="top">Cat # BE0067</td><td align="char" char="." valign="top">(1:100)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">Purified Rat anti-mouse CD3, Rat monoclonal, clone 17 A2</td><td align="left" valign="top">BioXCell</td><td align="left" valign="top">Cat # BE0002</td><td align="char" char="." valign="top">(1:50)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">Purified Rat anti-mouse CD8, Rat monoclonal, clone 53.6.72</td><td align="left" valign="top">BioXCell</td><td align="left" valign="top">Cat # BE0004-1</td><td align="char" char="." valign="top">(1:100)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">Purified Rat anti-mouse CD25, Rat monoclonal, clone PC-61.5.3</td><td align="left" valign="top">BioXCell</td><td align="left" valign="top">Cat # BE0012</td><td align="char" char="." valign="top">(1:100)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">Purified Rat anti-mouse CD11b, Rat monoclonal, clone M1/70</td><td align="left" valign="top">BioXCell</td><td align="left" valign="top">Cat # BE0007</td><td align="char" char="." valign="top">(1:100)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">Purified Rat anti-mouse Gr-1, Rat monoclonal, clone RB6-8C5</td><td align="left" valign="top">BioXCell</td><td align="left" valign="top">Cat # BE0075</td><td align="char" char="." valign="top">(1:100)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">Purified Rat anti-mouse Ter-119, Rat monoclonal, clone TER-119</td><td align="left" valign="top">BioXCell</td><td align="left" valign="top">Cat # BE0183</td><td align="char" char="." valign="top">(1:100)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">Alexa Fluor 594 AffiniPure Donkey anti-mouse IgG, Donkey polyclonal</td><td align="left" valign="top">Jackson ImmunoResearch</td><td align="left" valign="top">Cat # 715585151; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2340855">AB_2340855</ext-link></td><td align="char" char="." valign="top">(1:100)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">Goat anti-mouse CCL22, Polyclonal, Goat polyclonal</td><td align="left" valign="top">R&amp;D Systems</td><td align="left" valign="top">Cat # AF439; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_355360">AB_355360</ext-link></td><td align="char" char="." valign="top">(1.2 ug/mL)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">Normal Goat IgG control, Goat polyclonal</td><td align="left" valign="top">R&amp;D Systems</td><td align="left" valign="top">Cat # AB-108-C; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_354267">AB_354267</ext-link></td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">antibody</td><td align="left" valign="top">CD8a- Alexa Fluor 594, rat monoclonal, clone 53.6.7</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat# 100758</td><td align="char" char="." valign="top">(1:100)</td></tr><tr><td align="left" valign="top">Other flow cytometry reagents</td><td align="left" valign="top">Qdot 605 Streptavidin Conjugate</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat # Q10101MP</td><td align="char" char="." valign="top">(1:200)</td></tr><tr><td align="left" valign="top">Other immunostaining reagents</td><td align="left" valign="top">Streptavidin-Alexa Fluor 488</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat# S32354</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Other flow cytometry reagents</td><td align="left" valign="top">Ulex Europaeus Agglutinin I (UEAI), Biotinylated</td><td align="left" valign="top">Vector Laboratories</td><td align="left" valign="top">SKU B-1065–2</td><td align="char" char="." valign="top">(1:1000)</td></tr><tr><td align="left" valign="top">sequence-based reagent</td><td align="left" valign="top">CCL17 Forward</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib22">Cowan et al., 2014</xref></td><td align="left" valign="top">qPCR Primer</td><td align="left" valign="top">5’-<named-content content-type="sequence">AGTGGAGTGTTCCAGGGATG</named-content>-3’</td></tr><tr><td align="left" valign="top">sequence-based reagent</td><td align="left" valign="top">CCL17 Reverse</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib22">Cowan et al., 2014</xref></td><td align="left" valign="top">qPCR Primer</td><td align="left" valign="top">5’-<named-content content-type="sequence">CCAATCTGATGGCCTTCTTC</named-content>-3’</td></tr><tr><td align="left" valign="top">sequence-based reagent</td><td align="left" valign="top">CCL19 Forward</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib42">Kurd and Robey, 2016</xref></td><td align="left" valign="top">qPCR Primer</td><td align="left" valign="top">5’-<named-content content-type="sequence">GCTAATGATGCGGAAGACTG</named-content>-3’</td></tr><tr><td align="left" valign="top">sequence-based reagent</td><td align="left" valign="top">CCL19 Reverse</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib42">Kurd and Robey, 2016</xref></td><td align="left" valign="top">qPCR Primer</td><td align="left" valign="top">5’-<named-content content-type="sequence">ACTCACATCGACTCTCTAGG</named-content>-3’</td></tr><tr><td align="left" valign="top">sequence-based reagent</td><td align="left" valign="top">CCL21 Forward</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib67">Seach et al., 2008</xref></td><td align="left" valign="top">qPCR Primer</td><td align="left" valign="top">5’-<named-content content-type="sequence">GCAGTGATGGAGGGGGTCAG</named-content>-3’</td></tr><tr><td align="left" valign="top">sequence-based reagent</td><td align="left" valign="top">CCL21 Reverse</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib67">Seach et al., 2008</xref></td><td align="left" valign="top">qPCR Primer</td><td align="left" valign="top">5’-<named-content content-type="sequence">CGGGGTGAGAACAGGATTGC</named-content>-3’</td></tr><tr><td align="left" valign="top">sequence-based reagent</td><td align="left" valign="top">CCL22 Forward</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib33">Hu et al., 2015b</xref></td><td align="left" valign="top">qPCR Primer</td><td align="left" valign="top">5’-<named-content content-type="sequence">AGGTCCCTATGGTGCCAATGT</named-content>-3’</td></tr><tr><td align="left" valign="top">sequence-based reagent</td><td align="left" valign="top">CCL22 Reverse</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib33">Hu et al., 2015b</xref></td><td align="left" valign="top">qPCR Primer</td><td align="left" valign="top">5’- <named-content content-type="sequence">CGGCAGGATTTTGAGGTCCA</named-content>-3’</td></tr><tr><td align="left" valign="top">sequence-based reagent</td><td align="left" valign="top">β-actin Forward</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib18">Camara et al., 2019</xref></td><td align="left" valign="top">qPCR Primer</td><td align="left" valign="top">5’- <named-content content-type="sequence">CACTGTCGAGTCGCGTCCA</named-content>-3’</td></tr><tr><td align="left" valign="top">sequence-based reagent</td><td align="left" valign="top">β-actin Reverse</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib18">Camara et al., 2019</xref></td><td align="left" valign="top">qPCR Primer</td><td align="left" valign="top">5’- <named-content content-type="sequence">CATCCATGGCGAACTGGTGG</named-content>-3’</td></tr><tr><td align="left" valign="top">peptide, recombinant protein</td><td align="left" valign="top">Recombinant Murine CCL17</td><td align="left" valign="top">Peprotech</td><td align="left" valign="top">Cat # 250–43</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">peptide, recombinant protein</td><td align="left" valign="top">Recombinant Murine CCL19</td><td align="left" valign="top">Peprotech</td><td align="left" valign="top">Cat # 250-27B</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">peptide, recombinant protein</td><td align="left" valign="top">Recombinant Murine CCL21</td><td align="left" valign="top">Peprotech</td><td align="left" valign="top">Cat # 250–13</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">peptide, recombinant protein</td><td align="left" valign="top">Recombinant Murine CCL22</td><td align="left" valign="top">Peprotech</td><td align="left" valign="top">Cat # 250–23</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">peptide, recombinant protein</td><td align="left" valign="top">Recombinant Murine CXCL12</td><td align="left" valign="top">Peprotech</td><td align="left" valign="top">Cat # 250-20B</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">peptide, recombinant protein</td><td align="left" valign="top">Recombinant Mouse CCL25</td><td align="left" valign="top">R&amp;D Systems</td><td align="left" valign="top">Cat # 481-TK-025</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">commercial assay or kit</td><td align="left" valign="top">Fixation / Permeablization Kit (RUO)</td><td align="left" valign="top">BD</td><td align="left" valign="top">Cat # 554714</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">commercial assay or kit</td><td align="left" valign="top">CellTrace Violet cell proliferation kit</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat # C34557</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">commercial assay or kit</td><td align="left" valign="top">Celltracker Red CMTPX Dye</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat # C34552</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">commercial assay or kit</td><td align="left" valign="top">eBioscience Indo-1 AM Calcium Sensor Dye</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat # 65-0856-39</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">commercial assay or kit</td><td align="left" valign="top">TRIzol Reagent</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat # 15596026</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">commercial assay or kit</td><td align="left" valign="top">SYBR Green PCR Master Mix</td><td align="left" valign="top">Applied Biosystems</td><td align="left" valign="top">Cat # 4309155</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">commercial assay or kit</td><td align="left" valign="top">Mouse TLR1-9 Agonist Kit</td><td align="left" valign="top">Invivogen</td><td align="left" valign="top">Cat # tlrl-kit1mw</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">commercial assay or kit</td><td align="left" valign="top">Dynabeads sheep anti-rat IgG</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat # 11035</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">commercial assay or kit</td><td align="left" valign="top">ProLong Gold Antifade Mountant</td><td align="left" valign="top">ThermoFisher</td><td align="left" valign="top">Cat # P36930</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">software, algorithm</td><td align="left" valign="top">Flowjo v10.8.1</td><td align="left" valign="top">BD</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com/">https://www.flowjo.com/</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">software, algorithm</td><td align="left" valign="top">Graphpad PRISM v9.3.1</td><td align="left" valign="top">Graphpad Software</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">software, algorithm</td><td align="left" valign="top">Imaris v9.8.0</td><td align="left" valign="top">Oxford Instruments</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://imaris.oxinst.com/">https://imaris.oxinst.com/</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">software, algorithm</td><td align="left" valign="top">Biorender</td><td align="left" valign="top">Biorender</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://biorender.com/">https://biorender.com/</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">software, algorithm</td><td align="left" valign="top">ImageJ</td><td align="left" valign="top">NIH</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://imagej.nih.gov/">https://imagej.nih.gov/</ext-link></td><td align="left" valign="top"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mice</title><p>C57BL/6J (wild-type, Strain #: 000664), B6.SJL-Ptprc<sup>a</sup> PepC<sup>b</sup>/BoyJ (CD45.1, Strain #: 002014), C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-I, Strain #: 003831), B6.Cg-Tg(TcraTcrb)425Cbn/J (OT-II, Strain #: 004194), B6(Cg)-Rag2<sup>tm1.1Cgn</sup>/J (<italic>Rag2<sup>−/−</sup></italic>, Strain #: 008449), B6.129P2(C)Ccr7<sup>tm1Rfo</sup>r/J (<italic>Ccr7<sup>−/−</sup></italic>, Strain #: 006621), B6.129S2-H2<sup>dlAb1-Ea</sup>/J (<italic>MHCII<sup>−/−</sup></italic>, Strain #: 003584), B6.129P2-B2m<sup>tm1Unc</sup>/DcrJ (<italic>B2m<sup>−/−</sup></italic>, Strain #: 002087), and C57BL/6-Tg(Nr4a1-EGFP/cre)820Khog/J (<italic>Nr4a1<sup>GFP</sup></italic>, Strain #: 016617) were purchased from the Jackson Laboratory. <italic>Ccr4<sup>−/</sup></italic><sup>−</sup> (<xref ref-type="bibr" rid="bib21">Chvatchko et al., 2000</xref>), pCX-EGFP (<xref ref-type="bibr" rid="bib73">Wright et al., 2001</xref>), and Rag2p-GFP (<xref ref-type="bibr" rid="bib13">Boursalian et al., 2004</xref>) strains were generously provided by A.D. Luster (Massachusetts General Hospital, Boston, MA), Irving L. Weissman (Stanford University, Stanford, CA), and Ellen R. Richie (the University of Texas MD Anderson Center, Houston, TX), respectively. <italic>Ccr4<sup>−/−</sup>; Ccr7<sup>−/−</sup></italic> (DKO), OT-I <italic>Rag2<sup>−/−</sup></italic>, and OT-II <italic>Rag2<sup>−/−</sup> MHCII<sup>−/−</sup></italic> strains were bred in house. Experiments were performed using mice 4–8 weeks old, except for for autoimmune/inflammatory studies which were carried out in older mice, as specified. All strains were bred and maintained under specific pathogen-free conditions at the Animal Resources Center, the University of Texas at Austin, with procedure approval from the Institutional Animal Care and Use Committee, the University of Texas at Austin.</p></sec><sec id="s4-2"><title>Flow cytometry</title><p>5 × 10<sup>6</sup> thymocytes were stained with fluorescently conjugated antibodies and a viability dye, and incubated on ice for 30 min in the dark. Unless specified, for stains including anti-CCR7, cells were instead incubated in a 37°C water bath for 45 min in the dark. Stained cells were washed and resuspended in FACS Wash Buffer (phosphate-buffered saline [PBS] +2% fetal bovine serum [FBS]; GemCell, Gemini, CA, USA) + 1 µg/ml propidium iodine if a fixable viability dye was not used. For cleaved caspase 3 stains, surface-stained cells were fixed and permeabilized with the BD Cytofix/Cytoperm kit (BD, NJ, USA) according to the manufacturer’s instructions prior to staining for anti-cleaved caspase 3 (Cell Signaling Technology, MA, USA). All flow cytometry data were acquired on an LSR Fortessa flow cytometer (BD) or a FACSAria Fusion SORP cell sorter (BD) and analyzed with FlowJo ver.10.8.0 (BD).</p></sec><sec id="s4-3"><title>Transwell chemotaxis assays</title><p>Thymocyte chemotaxis assays were performed as previously described (<xref ref-type="bibr" rid="bib19">Campbell et al., 1999</xref>). Briefly, 5 × 10<sup>5</sup> thymocytes were resuspended in 100 µl RPMI 1640 (Gibco, MA, USA)+10% FBS (Gemini) and added to the top chamber of 5-µm pore transwell tissue culture inserts (Corning, NY, USA) in 24-well plates. The bottom chamber of the transwells contained recombinant mouse chemokines CCL17, CCL22, CCL19, CCL21 (Peprotech, NJ, USA), or CCL25 (R&amp;D Systems, MN, USA) at 100, 10, and 1 nM, diluted in 500 µl RPMI 1640 + 10% FBS. The plate was cultured at 37°C, 5% CO<sub>2</sub> for 2 hr. Cells that migrated to the bottom wells, and 5 × 10<sup>5</sup> input cells, were analyzed and quantified by flow cytometry. A standard number of 15 µm polyester beads were added to each well to calculate the absolute number of thymocytes that migrated. Migration percentages of each subset were calculated by dividing the number of migrated cells of each subset by the number of cells of the same subset in the input cell sample, and the migration index was calculated as the ratio of the migration percentage in wells containing chemokine to the average migration percentage in wells without chemokine (Blank wells).</p></sec><sec id="s4-4"><title>Ex vivo thymic slice preparation</title><p>Ex vivo thymic slices were prepared as previous described (<xref ref-type="bibr" rid="bib44">Lancaster and Ehrlich, 2017</xref>). Briefly, surgically removed thymi were cleaned of residual connective tissue, and the two lobes were separated and embedded in 4% low melting point agarose (Lonza, NJ, USA) in PBS. 400 µm thymic slices were generated by slicing the trimmed agarose blocks on a VT 1000S vibratome (Leica, Germany) and kept on ice, submerged in complete RPMI until addition of thymocytes. Slices were placed on 0.4-µm cell culture inserts (Millipore, MA, USA) in 35-mm dishes containing 1 ml complete RPMI (RPMI 1640 supplemented with 1× GlutaMAX, 1 mM sodium pyruvate, 1× penicillin–streptomycin–glutamine, 1× Minimum Essential Medium (MEM) non-essential amino acid, and 50 µM β-mercaptoethanol [All from Gibco], and 10% FBS [Gemini]).</p></sec><sec id="s4-5"><title>Synchronized positive selection thymic slice assays</title><p>Synchronized positive selection assays were set up as previously described (<xref ref-type="bibr" rid="bib64">Ross et al., 2014</xref>). Briefly, to generate a source of pre-positive selection OT-I thymocytes, bone marrow from OT-I <italic>Rag2<sup>−/−</sup></italic> hosts was magnetically depleted of CD3<sup>+</sup>, CD8<sup>+</sup>, CD25<sup>+</sup>, B220<sup>+</sup>, Gr-1<sup>+</sup>, CD11b<sup>+</sup>, and Ter119<sup>+</sup> cells using Rat anti-mouse antibodies (BioXcell, NH, USA) and Dynabeads sheep anti-rat IgG beads (Invitrogen, MA, USA) according to the manufacturer’s recommendations, then 10<sup>7</sup> cells were injected into lethally irradiated <italic>B2m<sup>−/−</sup></italic> hosts. The bone marrow chimera recipients were maintained for 4–6 weeks before collecting OT-I pre-selection thymocytes. For pre-positive selection OT-II thymocytes, OT-II <italic>Rag2<sup>−/−</sup> MHCII<sup>−/−</sup></italic> mice were bred. Thymic single-cell suspensions from the OT-I <italic>Rag2<sup>−/−</sup></italic> -&gt; <italic>B2m<sup>−/−</sup></italic> bone marrow chimeras or OT-II <italic>Rag2<sup>−/−</sup> MHCII<sup>−/−</sup></italic> mice were isolated, stained in 5 ml RPMI 1640 + 5 µM CellTrace Violet (Invitrogen; for flow cytometry) or CellTracker RedCMTPX (Thermo Fisher Scientific; for imaging) for 30 min in the dark at 37°C, washed once with warm complete RPMI, resuspended in fresh, warm complete RPMI, and kept in the dark at 37°C prior to slice addition. Prepared cells were overlaid on WT, <italic>B2m<sup>−/−</sup></italic>, <italic>MHCII<sup>−/−</sup></italic>, or pCX-EGFP slices and incubated at 5% CO<sub>2</sub> 37°C. Slices were gently washed at 3 hr with warm complete RPMI in a dish to prevent further entry of new cells. At the indicated time points, thymocytes were harvested by mechanical disruption of the slices for flow cytometry or intact slices were imaged by two-photon microscopy.</p></sec><sec id="s4-6"><title>Two-photon imaging and analysis of thymic slices</title><p>For imaging of purified thymocyte subsets, sorted cells from each host were centrifuged for collection, then separately stained in RPMI 1640 with 5 µM CellTracker Red CMTPX (Thermo Fisher Scientific, MA, USA) or Indo-1 AM (eBioscience, CA, USA) for 30 min in 37°C water bath, away from light. Dye used for each host was swapped between experiments to account for potential effect of dyes on cell viability and mobility. For imaging of pre-positive selection thymocytes, whole thymus single cells were stained in RPMI 1640 with 5 µM CellTracker Red CMTPX in the same way. Stained cells were collected by centrifugation and resuspended in fresh warm cRPMI, incubated for 30 min in 37°C water bath, away from light. Prepared cells were collected by centrifugation, then washed two times with fresh warm complete RPMI to remove dye residues, then laid onto pCX-EGFP slices, and incubated in 5% CO<sub>2</sub> incubator at 37°C for a minimum of 1 hr before two-photon imaging.</p><p>For image and video acquisition, thymic slices were secured to an imaging chamber (Harvard Apparatus, MA, USA) perfused with heated DRPMI (Corning) + 2 g/l sodium bicarbonate, 5 mM Hydroxyethylpiperazine Ethane Sulfonic Acid (HEPES) (Sigma-Aldrich, MA, USA) and 1.25 mM CaCl<sub>2</sub>, pH = 7.4, aerated with 95% O<sub>2</sub>+ 5% CO<sub>2</sub> at flow rate of 100 ml/hr. The imaging chamber is secured on a heated stage, and a temperature probe was inserted to monitor and maintain the chamber temperature at 37°C. Images were acquired using an Ultima IV microscope controlled by PrairieView software (V5.4, Bruker, MA, USA), with a ×20 water immersion objective, NA = 1.0 (Olympus, Japan). Time-lapse videos were acquired by a t-series of 60 rounds of 15 s acquisition, through 40 µm depth at 5 µm intervals. Samples were illuminated with a Mai Tai Ti:sapphire laser (Spectra Physics) tuned to 865 nm for simultaneous excitation of EGFP and CMTPX, and an additional InSight Ti:sapphire laser (Spectra Physics, CA, USA) tuned to 730 nm for excitation of Indo-1 AM, if necessary. Emitted light was passed through 473/24, 525/50, and 605/70 band pass filters (Chroma, VT, USA) to separate PMTs for detecting Indo-1 AM (low calcium), EGFP, and CMTPX signals, respectively.</p><p>Captured images were analyzed using Imaris v9.7.2 (Bitplane, Switzerland). For medullary enrichment analysis, medullary and cortical volumes were established by manually generating surface objects by morphological distinction. Fluorescently labeled cells were identified using Spot tools from random frames of each video, and medullary or cortical cellular localization was determined by calculating the spot’s distance to the medullary surface object using the Spot distance to Surface function in ImarisXT. Densities of cells within each region were calculated by dividing the number of cells in the respective region by the volume of the surface object, and medullary-to-cortical ratio was calculated by dividing the medullary density to the cortical density within the same video, using Excel (Microsoft). For thymocyte migration parameters, trajectory of thymocytes were established with the automated Spot tracking feature within Imaris. Only trajectories with time span ≥3 min were included in the analysis. Average track speed and straightness were generated by Imaris for analysis.</p></sec><sec id="s4-7"><title>cDNA preparation and qPCR</title><p>FACS purified, frozen thymic APC subsets were thawed and lysed in TRIzol (Thermo Fisher), RNA was extracted, and cDNA was synthesized using the qScript cDNA Synthesis Kit (QuantaBio, MA, USA), per manufacturer’s recommendations. qRT-PCR was performed using SYBR Green PCR Master Mix (Applied Biosystems, MA, USA), on a ViiA 7 Real-Time PCR System (Applied Biosystems), using the following primers: <italic>Ccl17</italic> Forward: 5′-AGT GGA GTG TTC CAG GGA TG-3′, <italic>Ccl17</italic> Reverse: 5′-CCA ATC TGA TGG CCT TCT TC-3′, <italic>Ccl19</italic> Forward: 5′-GCT AAT GAT GCG GAA GAC TG-3′, <italic>Ccl19</italic> Reverse: 5′-ACT CAC ATC GAC TCT CTA GG-3′, <italic>Ccl21</italic> Forward: 5′-GCA GTG ATG GAG GGG GTC AG-3′, <italic>Ccl21</italic> Reverse: 5′-CGG GGT GAG AAC AGG ATT GC-3′, <italic>Ccl22</italic> Forward: 5′-AGG TCC CTA TGG TGC CAA TGT-3′, <italic>Ccl22</italic> Reverse: 5′-CGG CAG GAT TTT GAG GTC CA-3′, β-actin Forward: 5′-CAC TGT CGA GTC GCG TCC A-3′, β-actin Reverse: 5′-CAT CCA TGG CGA ACT GGT GG-3′. ddCT Relative expression levels of target genes in each subset were quantified by first normalizing to actin expression within each subset, then normalizing between subsets for expression of target genes relative to a subset previously shown to express high levels of that gene. For CCL17 and CCL22, expression levels were normalized to cDC2. For CCL19 and CCL21, expression levels were normalized to mTEC<sup>lo</sup>.</p></sec><sec id="s4-8"><title>Congenic TLR stimulation and co-culture experiment</title><p>To activate APCs, congenic CD45.1 mouse spleen was isolated and red blood cells were lysed with RBC lysis buffer (BioLegend, CA, USA). Leukocytes were then resuspended in complete RPMI with 1 µg/ml high molecular weight poly(I:C), 1 µg/ml low molecular weight poly(I:C), 100 ng/ml LPS, 500 nM ODN1826 (Invivogen, CA, USA), or without any TLR ligands, and incubated in 5% CO<sub>2</sub> incubator at 37°C overnight. The next day, CD45.2 WT and <italic>Ccr4<sup>−/−</sup></italic> CD4<sup>+</sup> T cells were isolated from spleen by magnetically depleting CD8<sup>+</sup>, CD25<sup>+</sup>, B220<sup>+</sup>, CD11b<sup>+</sup>, Gr-1<sup>+</sup>, and Ter119<sup>+</sup> cells with corresponding rat anti-mouse antibodies (BioXCell) and Dynabeads sheep anti-rat IgG (Invitrogen), and resuspended in complete RPMI. Stimulated CD45.1 splenocytes were washed three times with fresh complete RPMI. 2.5 × 10<sup>4</sup> WT or <italic>Ccr4<sup>−/−</sup></italic> CD4<sup>+</sup> purified T cells were plated with or without 1.25 × 10<sup>5</sup> unstimulated or stimulated splenocytes per well in complete RPMI in a 96-well, U-bottom plate. At days 3 and 5, each well was harvested and subjected to flow cytometry analysis. 15-µm polyester beads of known quantities were added to quantify cells in each sample.</p></sec><sec id="s4-9"><title>Immunofluorescent analyses of thymic and LNs cryosections and detection of autoantibodies</title><p>To detect anti-nuclear autoantibodies in mouse serum, 7 µm cryosections were prepared from <italic>Rag2<sup>−/−</sup></italic> kidneys (C57BL/6J background). Cryosections were fixed in acetone (–20°C for 20 min), rinsed 3× (2× PBS rinses and 1× PBS with 0.1% Tween 20), blocked with 9% donkey serum (Jackson ImmunoResearch) in PBS for 20 min and incubated with undiluted mouse serum from mice of the indicated genotypes for 2 hr at room temperature. After washing, auto-antibodies were detected by staining with anti-mouse IgG AF594 in PBS for 1 hr at room temperature. After washing, slides were incubated with 4′,6-diamidino-2-phenylindole (DAPI), washed, and coverslips were mounted in ProLong Gold Antifade reagent (Thermo Fisher). For CCL22 immunofluorescent staining in thymus and inguinal lymph node immunostaining, 7 µm cryosections were prepared from the thymus of 1-month-old C57BL/6J mice and from lymph nodes of 5- to 6-month-old mice, respectively. All slides were fixed and stained as above. Thymus sections were stained with anti-CCL22, anti-CD11c-biotin, and anti-CD31-APC overnight at room temperature. After washing, sections were incubated with anti-goat-Dylight 488 and streptavidin Alexa Fluor 594 secondary antibodies for 1hr at room temperature. Inguinal lymph nodes were stained with anti-CD8a-AF594, anti-B220 -biotin, and anti-CD4-APC for 4 hours at room temperature. After washing, sections were incubated with streptavidin Alexa Fluor 488 for 1hr at room temperature. After washing, the DAPI nuclear stain was added and slides were mounted as above. Immunofluorescent images were acquired on a DMi8 microscope (Leica), using a ×10/0.4 NA objective or a ×20/0.7 NA objective. Stitched images were generated with LasX software (Leica). All images were uniformly processed and converted into Tiffs using Fiji software (ImageJ).</p></sec><sec id="s4-10"><title>H&amp;E staining and quantification</title><p>Lacrimal glands, submandibular glands, colon, and liver were extracted from 6- to 8-month-old mice and fixed in formalin (Fisherbrand) for 48 hr before storing in 70% ethanol. Organs were sent to the Histology and Immunohistochemistry Laboratory at the University of Texas San Antonio for embedding, sectioning, and staining. Spleen and mLNs were extracted and processed by the Histology and Tissue Processing core at the University of Texas MD Anderson Cancer Center Science Park (Smithville, TX). Histological analysis of spleen, inguinal lymph nodes, liver, and colon was done by a veterinary pathologist, while infiltrates in lacrimal and submandibular glands stains were analyzed in-house, as previously described (<xref ref-type="bibr" rid="bib47">Lieberman et al., 2015</xref>). Briefly, we scored foci composed of at least 50 mononuclear cells. In the cases where multiple foci coalesced, we assigned foci a score value of 3 for statistical analysis. The number of inflammatory foci per 10 mm<sup>2</sup> was calculated by counting the total number of foci by standard light microscopy using a ×10 objective and dividing that by the surface area of sections measured by Fiji software. Colon sections were scored by Dr. Hale, who was blinded to genotype, for mucosal changes such as hyperplasia and architectural distortion, inflammation severity, and the percentage of the tissue affected as described previously (<xref ref-type="bibr" rid="bib30">Hale et al., 2005</xref>), but were given a single score that reflected the entire segment examined (total possible scores ranged from 0 to 15).</p></sec><sec id="s4-11"><title>Statistical analysis</title><p>All statistical analysis was conducted using GraphPad PRISM v9.8 (GraphPad Software, CA, USA), with the corresponding statistical tests and multiple comparison corrections listed in the figure legends.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Project administration</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Writing – original draft</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved Institutional Animal Care and Use Committee (IACUC) protocol (# AUP-2019-00034) at the University of Texas at Austin.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-80443-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Compiled data used to generate graphs in all figures and figure supplements.</title></caption><media xlink:href="elife-80443-data1-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data in this study are included in <xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>. Data for individual components of figures are found on the corresponding tabs in the spreadsheet.</p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors thank the Animal Resource Center staff at the University of Texas at Austin for assistance with mouse maintenance, Dr. Jessica Lancaster for assistance with two-photon microscopy training, Richard Salinas at the Center for Biomedical Research Support, and Dr. Ellen Richie for providing advice. Graphical illustrations were created with <ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/">Biorender.com</ext-link>. This research was supported by a grant from the National Institutes of Health R01AI104870 to LIRE.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abramson</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Thymic epithelial cells</article-title><source>Annual Review of Immunology</source><volume>35</volume><fpage>85</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-051116-052320</pub-id><pub-id pub-id-type="pmid">28226225</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alam</surname><given-names>A</given-names></name><name><surname>Braun</surname><given-names>MY</given-names></name><name><surname>Hartgers</surname><given-names>F</given-names></name><name><surname>Lesage</surname><given-names>S</given-names></name><name><surname>Cohen</surname><given-names>L</given-names></name><name><surname>Hugo</surname><given-names>P</given-names></name><name><surname>Denis</surname><given-names>F</given-names></name><name><surname>Sékaly</surname><given-names>RP</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Specific activation of the cysteine protease CPP32 during the negative selection of T cells in the thymus</article-title><source>The Journal of Experimental Medicine</source><volume>186</volume><fpage>1503</fpage><lpage>1512</lpage><pub-id pub-id-type="doi">10.1084/jem.186.9.1503</pub-id><pub-id pub-id-type="pmid">9348308</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>MS</given-names></name><name><surname>Venanzi</surname><given-names>ES</given-names></name><name><surname>Klein</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Berzins</surname><given-names>SP</given-names></name><name><surname>Turley</surname><given-names>SJ</given-names></name><name><surname>von Boehmer</surname><given-names>H</given-names></name><name><surname>Bronson</surname><given-names>R</given-names></name><name><surname>Dierich</surname><given-names>A</given-names></name><name><surname>Benoist</surname><given-names>C</given-names></name><name><surname>Mathis</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Projection of an immunological self shadow within the thymus by the Aire protein</article-title><source>Science</source><volume>298</volume><fpage>1395</fpage><lpage>1401</lpage><pub-id pub-id-type="doi">10.1126/science.1075958</pub-id><pub-id pub-id-type="pmid">12376594</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>MS</given-names></name><name><surname>Su</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>AIRE expands: new roles in immune tolerance and beyond</article-title><source>Nature Reviews. Immunology</source><volume>16</volume><fpage>247</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1038/nri.2016.9</pub-id><pub-id pub-id-type="pmid">26972725</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ardouin</surname><given-names>L</given-names></name><name><surname>Luche</surname><given-names>H</given-names></name><name><surname>Chelbi</surname><given-names>R</given-names></name><name><surname>Carpentier</surname><given-names>S</given-names></name><name><surname>Shawket</surname><given-names>A</given-names></name><name><surname>Montanana Sanchis</surname><given-names>F</given-names></name><name><surname>Santa Maria</surname><given-names>C</given-names></name><name><surname>Grenot</surname><given-names>P</given-names></name><name><surname>Alexandre</surname><given-names>Y</given-names></name><name><surname>Grégoire</surname><given-names>C</given-names></name><name><surname>Fries</surname><given-names>A</given-names></name><name><surname>Vu Manh</surname><given-names>TP</given-names></name><name><surname>Tamoutounour</surname><given-names>S</given-names></name><name><surname>Crozat</surname><given-names>K</given-names></name><name><surname>Tomasello</surname><given-names>E</given-names></name><name><surname>Jorquera</surname><given-names>A</given-names></name><name><surname>Fossum</surname><given-names>E</given-names></name><name><surname>Bogen</surname><given-names>B</given-names></name><name><surname>Azukizawa</surname><given-names>H</given-names></name><name><surname>Bajenoff</surname><given-names>M</given-names></name><name><surname>Henri</surname><given-names>S</given-names></name><name><surname>Dalod</surname><given-names>M</given-names></name><name><surname>Malissen</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Broad and largely concordant molecular changes characterize tolerogenic and immunogenic dendritic cell maturation in thymus and periphery</article-title><source>Immunity</source><volume>45</volume><fpage>305</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.07.019</pub-id><pub-id pub-id-type="pmid">27533013</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atibalentja</surname><given-names>DF</given-names></name><name><surname>Byersdorfer</surname><given-names>CA</given-names></name><name><surname>Unanue</surname><given-names>ER</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Thymus-blood protein interactions are highly effective in negative selection and regulatory T cell induction</article-title><source>Journal of Immunology</source><volume>183</volume><fpage>7909</fpage><lpage>7918</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0902632</pub-id><pub-id pub-id-type="pmid">19933868</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Au-Yeung</surname><given-names>BB</given-names></name><name><surname>Melichar</surname><given-names>HJ</given-names></name><name><surname>Ross</surname><given-names>JO</given-names></name><name><surname>Cheng</surname><given-names>DA</given-names></name><name><surname>Zikherman</surname><given-names>J</given-names></name><name><surname>Shokat</surname><given-names>KM</given-names></name><name><surname>Robey</surname><given-names>EA</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Quantitative and temporal requirements revealed for Zap70 catalytic activity during T cell development</article-title><source>Nature Immunology</source><volume>15</volume><fpage>687</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1038/ni.2918</pub-id><pub-id pub-id-type="pmid">24908390</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azzam</surname><given-names>HS</given-names></name><name><surname>Grinberg</surname><given-names>A</given-names></name><name><surname>Lui</surname><given-names>K</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Shores</surname><given-names>EW</given-names></name><name><surname>Love</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>CD5 expression is developmentally regulated by T cell receptor (TCR) signals and TCR avidity</article-title><source>The Journal of Experimental Medicine</source><volume>188</volume><fpage>2301</fpage><lpage>2311</lpage><pub-id pub-id-type="doi">10.1084/jem.188.12.2301</pub-id><pub-id pub-id-type="pmid">9858516</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bendelac</surname><given-names>A</given-names></name><name><surname>Killeen</surname><given-names>N</given-names></name><name><surname>Littman</surname><given-names>DR</given-names></name><name><surname>Schwartz</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>A subset of CD4+ thymocytes selected by MHC class I molecules</article-title><source>Science</source><volume>263</volume><fpage>1774</fpage><lpage>1778</lpage><pub-id pub-id-type="doi">10.1126/science.7907820</pub-id><pub-id pub-id-type="pmid">7907820</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bleul</surname><given-names>CC</given-names></name><name><surname>Boehm</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Chemokines define distinct microenvironments in the developing thymus</article-title><source>European Journal of Immunology</source><volume>30</volume><fpage>3371</fpage><lpage>3379</lpage><pub-id pub-id-type="doi">10.1002/1521-4141(2000012)30:12&lt;3371::AID-IMMU3371&gt;3.0.CO;2-L</pub-id><pub-id pub-id-type="pmid">11093154</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonasio</surname><given-names>R</given-names></name><name><surname>Scimone</surname><given-names>ML</given-names></name><name><surname>Schaerli</surname><given-names>P</given-names></name><name><surname>Grabie</surname><given-names>N</given-names></name><name><surname>Lichtman</surname><given-names>AH</given-names></name><name><surname>von Andrian</surname><given-names>UH</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Clonal deletion of thymocytes by circulating dendritic cells homing to the thymus</article-title><source>Nature Immunology</source><volume>7</volume><fpage>1092</fpage><lpage>1100</lpage><pub-id pub-id-type="doi">10.1038/ni1385</pub-id><pub-id pub-id-type="pmid">16951687</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bornstein</surname><given-names>C</given-names></name><name><surname>Nevo</surname><given-names>S</given-names></name><name><surname>Giladi</surname><given-names>A</given-names></name><name><surname>Kadouri</surname><given-names>N</given-names></name><name><surname>Pouzolles</surname><given-names>M</given-names></name><name><surname>Gerbe</surname><given-names>F</given-names></name><name><surname>David</surname><given-names>E</given-names></name><name><surname>Machado</surname><given-names>A</given-names></name><name><surname>Chuprin</surname><given-names>A</given-names></name><name><surname>Tóth</surname><given-names>B</given-names></name><name><surname>Goldberg</surname><given-names>O</given-names></name><name><surname>Itzkovitz</surname><given-names>S</given-names></name><name><surname>Taylor</surname><given-names>N</given-names></name><name><surname>Jay</surname><given-names>P</given-names></name><name><surname>Zimmermann</surname><given-names>VS</given-names></name><name><surname>Abramson</surname><given-names>J</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Single-cell mapping of the thymic stroma identifies IL-25-producing tuft epithelial cells</article-title><source>Nature</source><volume>559</volume><fpage>622</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0346-1</pub-id><pub-id pub-id-type="pmid">30022162</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boursalian</surname><given-names>TE</given-names></name><name><surname>Golob</surname><given-names>J</given-names></name><name><surname>Soper</surname><given-names>DM</given-names></name><name><surname>Cooper</surname><given-names>CJ</given-names></name><name><surname>Fink</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Continued maturation of thymic emigrants in the periphery</article-title><source>Nature Immunology</source><volume>5</volume><fpage>418</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1038/ni1049</pub-id><pub-id pub-id-type="pmid">14991052</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breed</surname><given-names>ER</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Hogquist</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Measuring thymic clonal deletion at the population level</article-title><source>Journal of Immunology</source><volume>202</volume><fpage>3226</fpage><lpage>3233</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1900191</pub-id><pub-id pub-id-type="pmid">31010850</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brennecke</surname><given-names>P</given-names></name><name><surname>Reyes</surname><given-names>A</given-names></name><name><surname>Pinto</surname><given-names>S</given-names></name><name><surname>Rattay</surname><given-names>K</given-names></name><name><surname>Nguyen</surname><given-names>M</given-names></name><name><surname>Küchler</surname><given-names>R</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Kyewski</surname><given-names>B</given-names></name><name><surname>Steinmetz</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Single-cell transcriptome analysis reveals coordinated ectopic gene-expression patterns in medullary thymic epithelial cells</article-title><source>Nature Immunology</source><volume>16</volume><fpage>933</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1038/ni.3246</pub-id><pub-id pub-id-type="pmid">26237553</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Britschgi</surname><given-names>MR</given-names></name><name><surname>Link</surname><given-names>A</given-names></name><name><surname>Lissandrin</surname><given-names>TKA</given-names></name><name><surname>Luther</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Dynamic modulation of CCR7 expression and function on naive T lymphocytes in vivo</article-title><source>Journal of Immunology</source><volume>181</volume><fpage>7681</fpage><lpage>7688</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.11.7681</pub-id><pub-id pub-id-type="pmid">19017956</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brugnera</surname><given-names>E</given-names></name><name><surname>Bhandoola</surname><given-names>A</given-names></name><name><surname>Cibotti</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>Q</given-names></name><name><surname>Guinter</surname><given-names>TI</given-names></name><name><surname>Yamashita</surname><given-names>Y</given-names></name><name><surname>Sharrow</surname><given-names>SO</given-names></name><name><surname>Singer</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Coreceptor reversal in the thymus: signaled CD4+8+ thymocytes initially terminate CD8 transcription even when differentiating into CD8+ T cells</article-title><source>Immunity</source><volume>13</volume><fpage>59</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(00)00008-x</pub-id><pub-id pub-id-type="pmid">10933395</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camara</surname><given-names>A</given-names></name><name><surname>Cordeiro</surname><given-names>OG</given-names></name><name><surname>Alloush</surname><given-names>F</given-names></name><name><surname>Sponsel</surname><given-names>J</given-names></name><name><surname>Chypre</surname><given-names>M</given-names></name><name><surname>Onder</surname><given-names>L</given-names></name><name><surname>Asano</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Yagita</surname><given-names>H</given-names></name><name><surname>Ludewig</surname><given-names>B</given-names></name><name><surname>Flacher</surname><given-names>V</given-names></name><name><surname>Mueller</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Lymph node mesenchymal and endothelial stromal cells cooperate via the RANK-RANKL cytokine axis to shape the sinusoidal macrophage niche</article-title><source>Immunity</source><volume>50</volume><fpage>1467</fpage><lpage>1481</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.05.008</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>JJ</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Butcher</surname><given-names>EC</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Cutting edge: developmental switches in chemokine responses during T cell maturation</article-title><source>Journal of Immunology</source><volume>163</volume><fpage>2353</fpage><lpage>2357</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.163.5.2353</pub-id><pub-id pub-id-type="pmid">10452965</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cepeda</surname><given-names>S</given-names></name><name><surname>Cantu</surname><given-names>C</given-names></name><name><surname>Orozco</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Brown</surname><given-names>Z</given-names></name><name><surname>Semwal</surname><given-names>MK</given-names></name><name><surname>Venables</surname><given-names>T</given-names></name><name><surname>Anderson</surname><given-names>MS</given-names></name><name><surname>Griffith</surname><given-names>AV</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Age-associated decline in thymic B cell expression of Aire and Aire-dependent self-antigens</article-title><source>Cell Reports</source><volume>22</volume><fpage>1276</fpage><lpage>1287</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.01.015</pub-id><pub-id pub-id-type="pmid">29386114</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chvatchko</surname><given-names>Y</given-names></name><name><surname>Hoogewerf</surname><given-names>AJ</given-names></name><name><surname>Meyer</surname><given-names>A</given-names></name><name><surname>Alouani</surname><given-names>S</given-names></name><name><surname>Juillard</surname><given-names>P</given-names></name><name><surname>Buser</surname><given-names>R</given-names></name><name><surname>Conquet</surname><given-names>F</given-names></name><name><surname>Proudfoot</surname><given-names>AEI</given-names></name><name><surname>Wells</surname><given-names>TNC</given-names></name><name><surname>Power</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A key role for Cc chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock</article-title><source>The Journal of Experimental Medicine</source><volume>191</volume><fpage>1755</fpage><lpage>1764</lpage><pub-id pub-id-type="doi">10.1084/jem.191.10.1755</pub-id><pub-id pub-id-type="pmid">10811868</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowan</surname><given-names>JE</given-names></name><name><surname>McCarthy</surname><given-names>NI</given-names></name><name><surname>Parnell</surname><given-names>SM</given-names></name><name><surname>White</surname><given-names>AJ</given-names></name><name><surname>Bacon</surname><given-names>A</given-names></name><name><surname>Serge</surname><given-names>A</given-names></name><name><surname>Irla</surname><given-names>M</given-names></name><name><surname>Lane</surname><given-names>PJL</given-names></name><name><surname>Jenkinson</surname><given-names>EJ</given-names></name><name><surname>Jenkinson</surname><given-names>WE</given-names></name><name><surname>Anderson</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Differential requirement for CCR4 and CCR7 during the development of Innate and adaptive αβT cells in the adult thymus</article-title><source>Journal of Immunology</source><volume>193</volume><fpage>1204</fpage><lpage>1212</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1400993</pub-id><pub-id pub-id-type="pmid">24990081</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daley</surname><given-names>SR</given-names></name><name><surname>Hu</surname><given-names>DY</given-names></name><name><surname>Goodnow</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Helios marks strongly autoreactive CD4+ T cells in two major waves of thymic deletion distinguished by induction of PD-1 or NF-ΚB</article-title><source>The Journal of Experimental Medicine</source><volume>210</volume><fpage>269</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1084/jem.20121458</pub-id><pub-id pub-id-type="pmid">23337809</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeVoss</surname><given-names>J</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Johannes</surname><given-names>K</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Liou</surname><given-names>GI</given-names></name><name><surname>Rinn</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>H</given-names></name><name><surname>Caspi</surname><given-names>RR</given-names></name><name><surname>Fong</surname><given-names>L</given-names></name><name><surname>Anderson</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Spontaneous autoimmunity prevented by thymic expression of a single self-antigen</article-title><source>The Journal of Experimental Medicine</source><volume>203</volume><fpage>2727</fpage><lpage>2735</lpage><pub-id pub-id-type="doi">10.1084/jem.20061864</pub-id><pub-id pub-id-type="pmid">17116738</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dzhagalov</surname><given-names>IL</given-names></name><name><surname>Chen</surname><given-names>KG</given-names></name><name><surname>Herzmark</surname><given-names>P</given-names></name><name><surname>Robey</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Elimination of self-reactive T cells in the thymus: a timeline for negative selection</article-title><source>PLOS Biology</source><volume>11</volume><elocation-id>e1001566</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1001566</pub-id><pub-id pub-id-type="pmid">23700386</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrlich</surname><given-names>LIR</given-names></name><name><surname>Oh</surname><given-names>DY</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name><name><surname>Lewis</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Differential contribution of chemotaxis and substrate restriction to segregation of immature and mature thymocytes</article-title><source>Immunity</source><volume>31</volume><fpage>986</fpage><lpage>998</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2009.09.020</pub-id><pub-id pub-id-type="pmid">19962328</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ehrlich</surname><given-names>LIR</given-names></name></person-group><year iso-8601-date="2016">2016</year><chapter-title>Control of migration during Intrathymic T cell development</chapter-title><person-group person-group-type="editor"><name><surname>Ratcliffe</surname><given-names>MJH</given-names></name></person-group><source>Encyclopedia of Immunobiology</source><publisher-name>Elsevier</publisher-name><fpage>249</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-374279-7.04012-1</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Finnish-German APECED Consortium</collab></person-group><year iso-8601-date="1997">1997</year><article-title>An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains</article-title><source>Nature Genetics</source><volume>17</volume><fpage>399</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1038/ng1297-399</pub-id><pub-id pub-id-type="pmid">8988175</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>G</given-names></name><name><surname>Vallée</surname><given-names>S</given-names></name><name><surname>Rybakin</surname><given-names>V</given-names></name><name><surname>McGuire</surname><given-names>MV</given-names></name><name><surname>Ampudia</surname><given-names>J</given-names></name><name><surname>Brockmeyer</surname><given-names>C</given-names></name><name><surname>Salek</surname><given-names>M</given-names></name><name><surname>Fallen</surname><given-names>PR</given-names></name><name><surname>Hoerter</surname><given-names>JAH</given-names></name><name><surname>Munshi</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>YH</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Fox</surname><given-names>HS</given-names></name><name><surname>Sauer</surname><given-names>K</given-names></name><name><surname>Acuto</surname><given-names>O</given-names></name><name><surname>Gascoigne</surname><given-names>NRJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Themis controls thymocyte selection through regulation of T cell antigen receptor-mediated signaling</article-title><source>Nature Immunology</source><volume>10</volume><fpage>848</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1038/ni.1766</pub-id><pub-id pub-id-type="pmid">19597499</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hale</surname><given-names>LP</given-names></name><name><surname>Greer</surname><given-names>PK</given-names></name><name><surname>Trinh</surname><given-names>CT</given-names></name><name><surname>Gottfried</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Treatment with oral bromelain decreases colonic inflammation in the IL-10-deficient murine model of inflammatory bowel disease</article-title><source>Clinical Immunology</source><volume>116</volume><fpage>135</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2005.04.011</pub-id><pub-id pub-id-type="pmid">15936249</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawiger</surname><given-names>D</given-names></name><name><surname>Masilamani</surname><given-names>RF</given-names></name><name><surname>Bettelli</surname><given-names>E</given-names></name><name><surname>Kuchroo</surname><given-names>VK</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo</article-title><source>Immunity</source><volume>20</volume><fpage>695</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2004.05.002</pub-id><pub-id pub-id-type="pmid">15189735</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Lancaster</surname><given-names>JN</given-names></name><name><surname>Ehrlich</surname><given-names>LIR</given-names></name></person-group><year iso-8601-date="2015">2015a</year><article-title>The contribution of chemokines and migration to the induction of central tolerance in the thymus</article-title><source>Frontiers in Immunology</source><volume>6</volume><elocation-id>398</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2015.00398</pub-id><pub-id pub-id-type="pmid">26300884</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Lancaster</surname><given-names>JN</given-names></name><name><surname>Sasiponganan</surname><given-names>C</given-names></name><name><surname>Ehrlich</surname><given-names>LIR</given-names></name></person-group><year iso-8601-date="2015">2015b</year><article-title>CCR4 promotes medullary entry and thymocyte-dendritic cell interactions required for central tolerance</article-title><source>The Journal of Experimental Medicine</source><volume>212</volume><fpage>1947</fpage><lpage>1965</lpage><pub-id pub-id-type="doi">10.1084/jem.20150178</pub-id><pub-id pub-id-type="pmid">26417005</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>DY</given-names></name><name><surname>Yap</surname><given-names>JY</given-names></name><name><surname>Wirasinha</surname><given-names>RC</given-names></name><name><surname>Howard</surname><given-names>DR</given-names></name><name><surname>Goodnow</surname><given-names>CC</given-names></name><name><surname>Daley</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A timeline demarcating two waves of clonal deletion and Foxp3 upregulation during thymocyte development</article-title><source>Immunology and Cell Biology</source><volume>94</volume><fpage>357</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1038/icb.2015.95</pub-id><pub-id pub-id-type="pmid">26510893</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Van Nieuwenhuijze</surname><given-names>A</given-names></name><name><surname>Selden</surname><given-names>HJ</given-names></name><name><surname>Jarrett</surname><given-names>AM</given-names></name><name><surname>Sorace</surname><given-names>AG</given-names></name><name><surname>Yankeelov</surname><given-names>TE</given-names></name><name><surname>Liston</surname><given-names>A</given-names></name><name><surname>Ehrlich</surname><given-names>LIR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CCR7 modulates the generation of thymic regulatory T cells by altering the composition of the thymic dendritic cell compartment</article-title><source>Cell Reports</source><volume>21</volume><fpage>168</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.09.016</pub-id><pub-id pub-id-type="pmid">28978470</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadakia</surname><given-names>T</given-names></name><name><surname>Tai</surname><given-names>X</given-names></name><name><surname>Kruhlak</surname><given-names>M</given-names></name><name><surname>Wisniewski</surname><given-names>J</given-names></name><name><surname>Hwang</surname><given-names>IY</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Guinter</surname><given-names>TI</given-names></name><name><surname>Alag</surname><given-names>A</given-names></name><name><surname>Kehrl</surname><given-names>JH</given-names></name><name><surname>Zhuang</surname><given-names>Y</given-names></name><name><surname>Singer</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>E-protein-regulated expression of CXCR4 adheres preselection thymocytes to the thymic cortex</article-title><source>The Journal of Experimental Medicine</source><volume>216</volume><fpage>1749</fpage><lpage>1761</lpage><pub-id pub-id-type="doi">10.1084/jem.20182285</pub-id><pub-id pub-id-type="pmid">31201207</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ki</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>D</given-names></name><name><surname>Selden</surname><given-names>HJ</given-names></name><name><surname>Seita</surname><given-names>J</given-names></name><name><surname>Chung</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Iyer</surname><given-names>VR</given-names></name><name><surname>Ehrlich</surname><given-names>LIR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Global transcriptional profiling reveals distinct functions of thymic stromal subsets and age-related changes during thymic involution</article-title><source>Cell Reports</source><volume>9</volume><fpage>402</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.08.070</pub-id><pub-id pub-id-type="pmid">25284794</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>L</given-names></name><name><surname>Kyewski</surname><given-names>B</given-names></name><name><surname>Allen</surname><given-names>PM</given-names></name><name><surname>Hogquist</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see)</article-title><source>Nature Reviews. Immunology</source><volume>14</volume><fpage>377</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1038/nri3667</pub-id><pub-id pub-id-type="pmid">24830344</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>L</given-names></name><name><surname>Robey</surname><given-names>EA</given-names></name><name><surname>Hsieh</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Central CD4(+) T cell tolerance: deletion versus regulatory T cell differentiation</article-title><source>Nature Reviews. Immunology</source><volume>19</volume><fpage>7</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1038/s41577-018-0083-6</pub-id><pub-id pub-id-type="pmid">30420705</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koble</surname><given-names>C</given-names></name><name><surname>Kyewski</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The thymic medulla: a unique microenvironment for Intercellular self-antigen transfer</article-title><source>The Journal of Experimental Medicine</source><volume>206</volume><fpage>1505</fpage><lpage>1513</lpage><pub-id pub-id-type="doi">10.1084/jem.20082449</pub-id><pub-id pub-id-type="pmid">19564355</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozai</surname><given-names>M</given-names></name><name><surname>Kubo</surname><given-names>Y</given-names></name><name><surname>Katakai</surname><given-names>T</given-names></name><name><surname>Kondo</surname><given-names>H</given-names></name><name><surname>Kiyonari</surname><given-names>H</given-names></name><name><surname>Schaeuble</surname><given-names>K</given-names></name><name><surname>Luther</surname><given-names>SA</given-names></name><name><surname>Ishimaru</surname><given-names>N</given-names></name><name><surname>Ohigashi</surname><given-names>I</given-names></name><name><surname>Takahama</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Essential role of CCL21 in establishment of central self-tolerance in T cells</article-title><source>The Journal of Experimental Medicine</source><volume>214</volume><fpage>1925</fpage><lpage>1935</lpage><pub-id pub-id-type="doi">10.1084/jem.20161864</pub-id><pub-id pub-id-type="pmid">28611158</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurd</surname><given-names>N</given-names></name><name><surname>Robey</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>T-cell selection in the thymus: a spatial and temporal perspective</article-title><source>Immunological Reviews</source><volume>271</volume><fpage>114</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1111/imr.12398</pub-id><pub-id pub-id-type="pmid">27088910</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurobe</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Ueno</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>F</given-names></name><name><surname>Ohigashi</surname><given-names>I</given-names></name><name><surname>Seach</surname><given-names>N</given-names></name><name><surname>Arakaki</surname><given-names>R</given-names></name><name><surname>Hayashi</surname><given-names>Y</given-names></name><name><surname>Kitagawa</surname><given-names>T</given-names></name><name><surname>Lipp</surname><given-names>M</given-names></name><name><surname>Boyd</surname><given-names>RL</given-names></name><name><surname>Takahama</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>CCR7-dependent cortex-to-medulla migration of positively selected thymocytes is essential for establishing central tolerance</article-title><source>Immunity</source><volume>24</volume><fpage>165</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2005.12.011</pub-id><pub-id pub-id-type="pmid">16473829</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lancaster</surname><given-names>JN</given-names></name><name><surname>Ehrlich</surname><given-names>LIR</given-names></name></person-group><year iso-8601-date="2017">2017</year><chapter-title>Analysis of thymocyte migration, cellular interactions, and activation by multiphoton fluorescence microscopy of live Thymic slices</chapter-title><person-group person-group-type="editor"><name><surname>Rainger</surname><given-names>GE</given-names></name><name><surname>McGettrick</surname><given-names>HM</given-names></name></person-group><source>T-Cell Trafficking: Methods and Protocols</source><publisher-name>Springer</publisher-name><fpage>9</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-6931-9</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lancaster</surname><given-names>JN</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Ehrlich</surname><given-names>LIR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Chemokine-mediated choreography of thymocyte development and selection</article-title><source>Trends in Immunology</source><volume>39</volume><fpage>86</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.it.2017.10.007</pub-id><pub-id pub-id-type="pmid">29162323</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lancaster</surname><given-names>JN</given-names></name><name><surname>Thyagarajan</surname><given-names>HM</given-names></name><name><surname>Srinivasan</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Ehrlich</surname><given-names>LIR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Live-cell imaging reveals the relative contributions of antigen-presenting cell subsets to thymic central tolerance</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2220</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09727-4</pub-id><pub-id pub-id-type="pmid">31101805</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lieberman</surname><given-names>SM</given-names></name><name><surname>Kreiger</surname><given-names>PA</given-names></name><name><surname>Koretzky</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Reversible Lacrimal gland-protective regulatory T-cell dysfunction underlies male-specific autoimmune dacryoadenitis in the non-obese diabetic mouse model of Sjögren syndrome</article-title><source>Immunology</source><volume>145</volume><fpage>232</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1111/imm.12439</pub-id><pub-id pub-id-type="pmid">25581706</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Qi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Affinity-coupled CCL22 promotes positive selection in germinal centres</article-title><source>Nature</source><volume>592</volume><fpage>133</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03239-2</pub-id><pub-id pub-id-type="pmid">33597749</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lutes</surname><given-names>LK</given-names></name><name><surname>Steier</surname><given-names>Z</given-names></name><name><surname>McIntyre</surname><given-names>LL</given-names></name><name><surname>Pandey</surname><given-names>S</given-names></name><name><surname>Kaminski</surname><given-names>J</given-names></name><name><surname>Hoover</surname><given-names>AR</given-names></name><name><surname>Ariotti</surname><given-names>S</given-names></name><name><surname>Streets</surname><given-names>A</given-names></name><name><surname>Yosef</surname><given-names>N</given-names></name><name><surname>Robey</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>T cell self-reactivity during thymic development dictates the timing of positive selection</article-title><source>eLife</source><volume>10</volume><elocation-id>e65435</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.65435</pub-id><pub-id pub-id-type="pmid">33884954</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchetti</surname><given-names>MC</given-names></name><name><surname>Di Marco</surname><given-names>B</given-names></name><name><surname>Cifone</surname><given-names>G</given-names></name><name><surname>Migliorati</surname><given-names>G</given-names></name><name><surname>Riccardi</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Dexamethasone-induced apoptosis of thymocytes: role of glucocorticoid receptor-associated Src kinase and caspase-8 activation</article-title><source>Blood</source><volume>101</volume><fpage>585</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1182/blood-2002-06-1779</pub-id><pub-id pub-id-type="pmid">12393559</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathis</surname><given-names>D</given-names></name><name><surname>Benoist</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A decade of AIRE</article-title><source>Nature Reviews. Immunology</source><volume>7</volume><fpage>645</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1038/nri2136</pub-id><pub-id pub-id-type="pmid">17641664</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCaughtry</surname><given-names>TM</given-names></name><name><surname>Wilken</surname><given-names>MS</given-names></name><name><surname>Hogquist</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Thymic emigration revisited</article-title><source>The Journal of Experimental Medicine</source><volume>204</volume><fpage>2513</fpage><lpage>2520</lpage><pub-id pub-id-type="doi">10.1084/jem.20070601</pub-id><pub-id pub-id-type="pmid">17908937</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCaughtry</surname><given-names>TM</given-names></name><name><surname>Baldwin</surname><given-names>TA</given-names></name><name><surname>Wilken</surname><given-names>MS</given-names></name><name><surname>Hogquist</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Clonal deletion of thymocytes can occur in the cortex with no involvement of the medulla</article-title><source>The Journal of Experimental Medicine</source><volume>205</volume><fpage>2575</fpage><lpage>2584</lpage><pub-id pub-id-type="doi">10.1084/jem.20080866</pub-id><pub-id pub-id-type="pmid">18936237</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melichar</surname><given-names>HJ</given-names></name><name><surname>Ross</surname><given-names>JO</given-names></name><name><surname>Herzmark</surname><given-names>P</given-names></name><name><surname>Hogquist</surname><given-names>KA</given-names></name><name><surname>Robey</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Distinct temporal patterns of T cell receptor signaling during positive versus negative selection in situ</article-title><source>Science Signaling</source><volume>6</volume><elocation-id>ra92</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2004400</pub-id><pub-id pub-id-type="pmid">24129702</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meredith</surname><given-names>M</given-names></name><name><surname>Zemmour</surname><given-names>D</given-names></name><name><surname>Mathis</surname><given-names>D</given-names></name><name><surname>Benoist</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Aire controls gene expression in the thymic epithelium with ordered stochasticity</article-title><source>Nature Immunology</source><volume>16</volume><fpage>942</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1038/ni.3247</pub-id><pub-id pub-id-type="pmid">26237550</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misslitz</surname><given-names>A</given-names></name><name><surname>Pabst</surname><given-names>O</given-names></name><name><surname>Hintzen</surname><given-names>G</given-names></name><name><surname>Ohl</surname><given-names>L</given-names></name><name><surname>Kremmer</surname><given-names>E</given-names></name><name><surname>Petrie</surname><given-names>HT</given-names></name><name><surname>Förster</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Thymic T cell development and progenitor localization depend on CCR7</article-title><source>The Journal of Experimental Medicine</source><volume>200</volume><fpage>481</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1084/jem.20040383</pub-id><pub-id pub-id-type="pmid">15302903</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moran</surname><given-names>AE</given-names></name><name><surname>Holzapfel</surname><given-names>KL</given-names></name><name><surname>Xing</surname><given-names>Y</given-names></name><name><surname>Cunningham</surname><given-names>NR</given-names></name><name><surname>Maltzman</surname><given-names>JS</given-names></name><name><surname>Punt</surname><given-names>J</given-names></name><name><surname>Hogquist</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse</article-title><source>The Journal of Experimental Medicine</source><volume>208</volume><fpage>1279</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1084/jem.20110308</pub-id><pub-id pub-id-type="pmid">21606508</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagamine</surname><given-names>K</given-names></name><name><surname>Peterson</surname><given-names>P</given-names></name><name><surname>Scott</surname><given-names>HS</given-names></name><name><surname>Kudoh</surname><given-names>J</given-names></name><name><surname>Minoshima</surname><given-names>S</given-names></name><name><surname>Heino</surname><given-names>M</given-names></name><name><surname>Krohn</surname><given-names>KJ</given-names></name><name><surname>Lalioti</surname><given-names>MD</given-names></name><name><surname>Mullis</surname><given-names>PE</given-names></name><name><surname>Antonarakis</surname><given-names>SE</given-names></name><name><surname>Kawasaki</surname><given-names>K</given-names></name><name><surname>Asakawa</surname><given-names>S</given-names></name><name><surname>Ito</surname><given-names>F</given-names></name><name><surname>Shimizu</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Positional cloning of the APECED Gene</article-title><source>Nature Genetics</source><volume>17</volume><fpage>393</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1038/ng1297-393</pub-id><pub-id pub-id-type="pmid">9398839</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nitta</surname><given-names>T</given-names></name><name><surname>Nitta</surname><given-names>S</given-names></name><name><surname>Lei</surname><given-names>Y</given-names></name><name><surname>Lipp</surname><given-names>M</given-names></name><name><surname>Takahama</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>CCR7-mediated migration of developing thymocytes to the medulla is essential for negative selection to tissue-restricted antigens</article-title><source>PNAS</source><volume>106</volume><fpage>17129</fpage><lpage>17133</lpage><pub-id pub-id-type="doi">10.1073/pnas.0906956106</pub-id><pub-id pub-id-type="pmid">19805112</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>N</given-names></name><name><surname>Barczak</surname><given-names>AJ</given-names></name><name><surname>Barbeau</surname><given-names>R</given-names></name><name><surname>Erle</surname><given-names>DJ</given-names></name><name><surname>Shin</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>CD40 mediates maturation of thymic dendritic cells driven by self-reactive CD4<sup>+</sup> thymocytes and supports development of natural regulatory T cells</article-title><source>Journal of Immunology</source><volume>200</volume><fpage>1399</fpage><lpage>1412</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1700768</pub-id><pub-id pub-id-type="pmid">29321275</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perera</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Gudjonson</surname><given-names>H</given-names></name><name><surname>Kalinina</surname><given-names>O</given-names></name><name><surname>Benichou</surname><given-names>JIC</given-names></name><name><surname>Block</surname><given-names>KE</given-names></name><name><surname>Louzoun</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>D</given-names></name><name><surname>Chong</surname><given-names>AS</given-names></name><name><surname>Dinner</surname><given-names>AR</given-names></name><name><surname>Weigert</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Self-antigen-driven Thymic B cell class switching promotes T cell central tolerance</article-title><source>Cell Reports</source><volume>17</volume><fpage>387</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.09.011</pub-id><pub-id pub-id-type="pmid">27705788</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Persaud</surname><given-names>SP</given-names></name><name><surname>Parker</surname><given-names>CR</given-names></name><name><surname>Lo</surname><given-names>WL</given-names></name><name><surname>Weber</surname><given-names>KS</given-names></name><name><surname>Allen</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Intrinsic CD4+ T cell sensitivity and response to a pathogen are set and sustained by avidity for thymic and peripheral complexes of self peptide and MHC</article-title><source>Nature Immunology</source><volume>15</volume><fpage>266</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1038/ni.2822</pub-id><pub-id pub-id-type="pmid">24487322</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrie</surname><given-names>HT</given-names></name><name><surname>Zúñiga-Pflücker</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Zoned out: functional mapping of stromal signaling microenvironments in the thymus</article-title><source>Annual Review of Immunology</source><volume>25</volume><fpage>649</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.23.021704.115715</pub-id><pub-id pub-id-type="pmid">17291187</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>JO</given-names></name><name><surname>Melichar</surname><given-names>HJ</given-names></name><name><surname>Au-Yeung</surname><given-names>BB</given-names></name><name><surname>Herzmark</surname><given-names>P</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name><name><surname>Robey</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Distinct phases in the positive selection of Cd8+ T cells distinguished by intrathymic migration and T-cell receptor signaling patterns</article-title><source>PNAS</source><volume>111</volume><fpage>E2550</fpage><lpage>E2558</lpage><pub-id pub-id-type="doi">10.1073/pnas.1408482111</pub-id><pub-id pub-id-type="pmid">24927565</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruscher</surname><given-names>R</given-names></name><name><surname>Kummer</surname><given-names>RL</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Jameson</surname><given-names>SC</given-names></name><name><surname>Hogquist</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CD8αα intraepithelial lymphocytes arise from two main thymic precursors</article-title><source>Nature Immunology</source><volume>18</volume><fpage>771</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1038/ni.3751</pub-id><pub-id pub-id-type="pmid">28530714</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sansom</surname><given-names>SN</given-names></name><name><surname>Shikama-Dorn</surname><given-names>N</given-names></name><name><surname>Zhanybekova</surname><given-names>S</given-names></name><name><surname>Nusspaumer</surname><given-names>G</given-names></name><name><surname>Macaulay</surname><given-names>IC</given-names></name><name><surname>Deadman</surname><given-names>ME</given-names></name><name><surname>Heger</surname><given-names>A</given-names></name><name><surname>Ponting</surname><given-names>CP</given-names></name><name><surname>Holländer</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Population and single-cell genomics reveal the Aire dependency, relief from <italic>Polycomb</italic> silencing, and distribution of self-antigen expression in thymic epithelia</article-title><source>Genome Research</source><volume>24</volume><fpage>1918</fpage><lpage>1931</lpage><pub-id pub-id-type="doi">10.1101/gr.171645.113</pub-id><pub-id pub-id-type="pmid">25224068</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seach</surname><given-names>N</given-names></name><name><surname>Ueno</surname><given-names>T</given-names></name><name><surname>Fletcher</surname><given-names>AL</given-names></name><name><surname>Lowen</surname><given-names>T</given-names></name><name><surname>Mattesich</surname><given-names>M</given-names></name><name><surname>Engwerda</surname><given-names>CR</given-names></name><name><surname>Scott</surname><given-names>HS</given-names></name><name><surname>Ware</surname><given-names>CF</given-names></name><name><surname>Chidgey</surname><given-names>AP</given-names></name><name><surname>Gray</surname><given-names>DHD</given-names></name><name><surname>Boyd</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The lymphotoxin pathway regulates Aire-independent expression of ectopic genes and chemokines in thymic stromal cells</article-title><source>Journal of Immunology</source><volume>180</volume><fpage>5384</fpage><lpage>5392</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.180.8.5384</pub-id><pub-id pub-id-type="pmid">18390720</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinclair</surname><given-names>C</given-names></name><name><surname>Bains</surname><given-names>I</given-names></name><name><surname>Yates</surname><given-names>AJ</given-names></name><name><surname>Seddon</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Asymmetric thymocyte death underlies the Cd4:Cd8 T-cell ratio in the adaptive immune system</article-title><source>PNAS</source><volume>110</volume><fpage>E2905</fpage><lpage>E2914</lpage><pub-id pub-id-type="doi">10.1073/pnas.1304859110</pub-id><pub-id pub-id-type="pmid">23858460</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stritesky</surname><given-names>GL</given-names></name><name><surname>Xing</surname><given-names>Y</given-names></name><name><surname>Erickson</surname><given-names>JR</given-names></name><name><surname>Kalekar</surname><given-names>LA</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Mueller</surname><given-names>DL</given-names></name><name><surname>Jameson</surname><given-names>SC</given-names></name><name><surname>Hogquist</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Murine thymic selection quantified using a unique method to capture deleted T cells</article-title><source>PNAS</source><volume>110</volume><fpage>4679</fpage><lpage>4684</lpage><pub-id pub-id-type="doi">10.1073/pnas.1217532110</pub-id><pub-id pub-id-type="pmid">23487759</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueno</surname><given-names>T</given-names></name><name><surname>Hara</surname><given-names>K</given-names></name><name><surname>Willis</surname><given-names>MS</given-names></name><name><surname>Malin</surname><given-names>MA</given-names></name><name><surname>Höpken</surname><given-names>UE</given-names></name><name><surname>Gray</surname><given-names>DHD</given-names></name><name><surname>Matsushima</surname><given-names>K</given-names></name><name><surname>Lipp</surname><given-names>M</given-names></name><name><surname>Springer</surname><given-names>TA</given-names></name><name><surname>Boyd</surname><given-names>RL</given-names></name><name><surname>Yoshie</surname><given-names>O</given-names></name><name><surname>Takahama</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Role for CCR7 ligands in the emigration of newly generated T lymphocytes from the neonatal thymus</article-title><source>Immunity</source><volume>16</volume><fpage>205</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(02)00267-4</pub-id><pub-id pub-id-type="pmid">11869682</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueno</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>F</given-names></name><name><surname>Gray</surname><given-names>DHD</given-names></name><name><surname>Kuse</surname><given-names>S</given-names></name><name><surname>Hieshima</surname><given-names>K</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name><name><surname>Kakiuchi</surname><given-names>T</given-names></name><name><surname>Lipp</surname><given-names>M</given-names></name><name><surname>Boyd</surname><given-names>RL</given-names></name><name><surname>Takahama</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Ccr7 signals are essential for cortex-medulla migration of developing thymocytes</article-title><source>The Journal of Experimental Medicine</source><volume>200</volume><fpage>493</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1084/jem.20040643</pub-id><pub-id pub-id-type="pmid">15302902</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollmann</surname><given-names>EH</given-names></name><name><surname>Rattay</surname><given-names>K</given-names></name><name><surname>Barreiro</surname><given-names>O</given-names></name><name><surname>Thiriot</surname><given-names>A</given-names></name><name><surname>Fuhlbrigge</surname><given-names>RA</given-names></name><name><surname>Vrbanac</surname><given-names>V</given-names></name><name><surname>Kim</surname><given-names>KW</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name><name><surname>Tager</surname><given-names>AM</given-names></name><name><surname>von Andrian</surname><given-names>UH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Specialized transendothelial dendritic cells mediate thymic T-cell selection against blood-borne macromolecules</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>6230</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-26446-x</pub-id><pub-id pub-id-type="pmid">34711828</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>DE</given-names></name><name><surname>Cheshier</surname><given-names>SH</given-names></name><name><surname>Wagers</surname><given-names>AJ</given-names></name><name><surname>Randall</surname><given-names>TD</given-names></name><name><surname>Christensen</surname><given-names>JL</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Cyclophosphamide/granulocyte colony-stimulating factor causes selective mobilization of bone marrow hematopoietic stem cells into the blood after M phase of the cell cycle</article-title><source>Blood</source><volume>97</volume><fpage>2278</fpage><lpage>2285</lpage><pub-id pub-id-type="doi">10.1182/blood.v97.8.2278</pub-id><pub-id pub-id-type="pmid">11290588</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Jameson</surname><given-names>SC</given-names></name><name><surname>Hogquist</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Late stages of T cell maturation in the thymus involve NF-ΚB and tonic type I interferon signaling</article-title><source>Nature Immunology</source><volume>17</volume><fpage>565</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1038/ni.3419</pub-id><pub-id pub-id-type="pmid">27043411</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamano</surname><given-names>T</given-names></name><name><surname>Nedjic</surname><given-names>J</given-names></name><name><surname>Hinterberger</surname><given-names>M</given-names></name><name><surname>Steinert</surname><given-names>M</given-names></name><name><surname>Koser</surname><given-names>S</given-names></name><name><surname>Pinto</surname><given-names>S</given-names></name><name><surname>Gerdes</surname><given-names>N</given-names></name><name><surname>Lutgens</surname><given-names>E</given-names></name><name><surname>Ishimaru</surname><given-names>N</given-names></name><name><surname>Busslinger</surname><given-names>M</given-names></name><name><surname>Brors</surname><given-names>B</given-names></name><name><surname>Kyewski</surname><given-names>B</given-names></name><name><surname>Klein</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Thymic B cells are licensed to present self antigens for central T cell tolerance induction</article-title><source>Immunity</source><volume>42</volume><fpage>1048</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.05.013</pub-id><pub-id pub-id-type="pmid">26070482</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zegarra-Ruiz</surname><given-names>DF</given-names></name><name><surname>Kim</surname><given-names>DV</given-names></name><name><surname>Norwood</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>WJH</given-names></name><name><surname>Saldana-Morales</surname><given-names>FB</given-names></name><name><surname>Hill</surname><given-names>AA</given-names></name><name><surname>Majumdar</surname><given-names>S</given-names></name><name><surname>Orozco</surname><given-names>S</given-names></name><name><surname>Bell</surname><given-names>R</given-names></name><name><surname>Round</surname><given-names>JL</given-names></name><name><surname>Longman</surname><given-names>RS</given-names></name><name><surname>Egawa</surname><given-names>T</given-names></name><name><surname>Bettini</surname><given-names>ML</given-names></name><name><surname>Diehl</surname><given-names>GE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Thymic development of gut-microbiota-specific T cells</article-title><source>Nature</source><volume>594</volume><fpage>413</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03531-1</pub-id><pub-id pub-id-type="pmid">33981034</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80443.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zúñiga-Pflücker</surname><given-names>Juan Carlos</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03dbr7087</institution-id><institution>University of Toronto, Sunnybrook Research Institute</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.04.03.486911" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.04.03.486911"/></front-stub><body><p>This important paper reveals the key steps associated with intrathymic central tolerance. Using elegant live imaging approaches, the authors provide convincing evidence in support of an updated model for how positive-selected thymocytes are called into the thymus medulla to interact with distinct antigen-presenting cells. The work makes an important contribution to the field by identifying previously unappreciated complexities related to cellular movement during T cell generation.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80443.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Zúñiga-Pflücker</surname><given-names>Juan Carlos</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03dbr7087</institution-id><institution>University of Toronto, Sunnybrook Research Institute</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Zúñiga-Pflücker</surname><given-names>Juan Carlos</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03dbr7087</institution-id><institution>University of Toronto, Sunnybrook Research Institute</institution></institution-wrap><country>Canada</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Takahama</surname><given-names>Yousuke</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id><institution>National Cancer Institute, National Institutes of Health</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.04.03.486911">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.04.03.486911v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;CCR4 and CCR7 differentially regulate thymocyte localization with distinct outcomes for central tolerance&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Juan Carlos Zúñiga-Pflücker as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Tadatsugu Taniguchi as the Senior Editor. The following individuals involved in the review of your submission have agreed to reveal their identity: Yousuke Takahama (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) It was felt that a more focused manuscript examining CCR4 expression and function would increase the impact of the work. In particular, lessening the reporting of previously established expression and function of CCR7.</p><p>2) More careful description and/or interpretation of the results from the caspase-3 analysis are encouraged, as well as, whether thymocytes make direct contact with CCR4-ligand expressing cells.</p><p>3) Please carefully consider and address the concerns raised by the reviewers.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>One outstanding question that remains is whether mice that are deficient for both CCR4 and CCR7, or even CCR4 alone, would show an increased incidence of spontaneous autoimmunity or auto-inflammatory outcomes. Have the author's noted or looked for any evidence of whether a break in tolerance leads to pathological consequences. This would nicely support their findings in Figure 7.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Figure 5C: All the density data look smaller in CCR7-/- than WT. Paired comparison between WT and CCR7-/- data should be additionally shown. The role of CCR4 is better evaluated by comparing the impacts of CCR4 and CCR7.</p><p>Figure 6C, D: These experiments measured caspase 3 cleavage in thymocyte subpopulations. Caspase 3 cleavage reflects apoptosis of thymocytes induced by various signals including glucocorticoid hormones (Alam, et al. J Exp Med. 1997 and Marchetti, et al. Blood 2003). It was also reported that caspase 3 inhibition does not always inhibit the negative selection of thymocytes (Doerfler, et al. J Immunol. 2000). Thus, the figure panels should specify the measurement of caspase 3 cleavage, and the text should convey a careful interpretation of the data with the biology of negative selection.</p><p>Figure 7A, B: Some DCs, including cDC2, are reported to be localized in the cortex within the thymus (Baba, et al., J Immunol. 2009). Also, thymocyte-DC interactions in the cortex are visualized to be CCR7-dependent (Ladi, et al. J Immunol. 2008). Whether cDC2 and CCR7+ cDCs are localized in the thymic cortex or the medulla is important to verify the possibility that CCR4 promotes the medullary migration of thymocytes. CCR4 may be more important for thymocyte-DC interaction in the cortex for the early phase of negative selection than promoting thymocyte migration to the medulla.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>1. In Figure 6, the authors examine 'early-phase' and 'late-phase' clonal deletion in various mice. Measurement of 'early-phase' clonal deletion does not appear to be impacted by combined CCR4/CCR7 deficiency. Can the authors comment on this finding?</p><p>2. Generally, the impact of CCR4 signaling on thymocyte 'outputs' is modest in comparison to CCR7 signaling (migration – Figure 2, medullary accumulation – Figure 5). This doesn't appear to be discussed. Is this due to the stage of the thymocyte stage and that TCR signaled DP and SM thymocytes are less responsive generally or do the authors think there are other factors? This may be pertinent to the authors' findings of reduced responsiveness of more immature, TCR signaled cells to CXCR4 ligands.</p><p>3. Throughout the manuscript the authors refer to DP CD3lo CD69+ cells and DP CD3+ CD69+ cells as post-positive selection. In a polyclonal repertoire, separating &quot;TCR signaled&quot; (CD69+) thymocytes into those that received positive selection signals versus negative selection signals is difficult. This description of 'post-positive selection' seems inaccurate and unsubstantiated. Have the authors examined Helios expression or expression of other markers (Nur77) to bolster their descriptions?</p><p>4. This is a minor point, but when the authors are discussing the cell populations present/absent in b2m-/- mice, there are obviously cells restricted by non-classical MHC-I as well as classical MHC-I that would be impacted. This should be appropriately considered (lines 102-118 for instance).</p><p>5. In the legend of figure 5 (or figure 5 itself), the time point of analysis does not appear to be stated.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80443.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>Reviewer #1 (Recommendations for the authors):</p><p>One outstanding question that remains is whether mice that are deficient for both CCR4 and CCR7, or even CCR4 alone, would show an increased incidence of spontaneous autoimmunity or auto-inflammatory outcomes. Have the author's noted or looked for any evidence of whether a break in tolerance leads to pathological consequences. This would nicely support their findings in Figure 7.</p></disp-quote><p>We thank the reviewer for this suggestion. We agree that an important implication of our model is that deficiency in CCR4 and/or CCR7 could result in an increased risk of spontaneous autoimmunity, which we have assessed in additional experiments. The link between CCR7 deficiency and autoimmunity has been well documented (Davalos-Misslitz, Rieckenberg, et al., 2007; Davalos-Misslitz, Worbs, et al., 2007; Kozai et al., 2017; Kurobe et al., 2006), and our previous study showed that CCR4 deficiency leads to increased lymphocytic infiltrates in lacrimal glands and circulating anti-nuclear autoantibodies in mice approaching 12-months of age (Hu et al., 2015). We’ve now highlighted these results in our revised text. In addition, because we find that CCR4 and CCR7 synergize to promote polyclonal negative selection and individually impact tolerance of different stages of developing thymocytes (Figure 6C), we evaluated whether distinct autoimmune manifestations would emerge in <italic>Ccr4<sup>-/-</sup>, Ccr7<sup>-/-</sup></italic>, and <italic>Ccr4<sup>-/</sup> Ccr7<sup>-/-</sup></italic> mice at 4.5-6.5 months of age. Notably, severe inflammation in the colon was evident only in <italic>Ccr4<sup>-/</sup> Ccr7<sup>-/-</sup></italic> mice, with a trend towards epithelial hyperplasia in <italic>Ccr4</italic><sup>-/-</sup> mice (Figure 7A). <italic>Ccr7</italic> deficiency and double deficiency resulted in lymphocytic infiltrates in endocrine organs and liver inflammation, consistent with a more prominent role for CCR7 in sustaining tolerance to tissue-specific antigens (Figure 7B and Figure 7—figure supplement 1B-D). In addition, lymphoid hyperplasia was observed in secondary lymphoid organs of <italic>Ccr4<sup>-/-</sup></italic> but not <italic>Ccr7<sup>-/-</sup></italic> mice (Figure 7C), and disorganized T cell zones were evident in <italic>Ccr4</italic><sup>-/-</sup> lymph nodes (Figure 7C). These results are consistent with our finding that CCR4 induces T-cell tolerance to self-antigens displayed by professional antigen presenting cells (Figure 7F). We discuss these findings and their implications in our revised Results and Discussion.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Figure 5C: All the density data look smaller in CCR7-/- than WT. Paired comparison between WT and CCR7-/- data should be additionally shown. The role of CCR4 is better evaluated by comparing the impacts of CCR4 and CCR7.</p></disp-quote><p>We thank the reviewer for this sharp observation. As requested, we have carried out additional 2-photon imaging experiments, pairing sorted WT and <italic>Ccr7<sup>-/-</sup></italic> thymocyte subsets. These paired analyses reveal that CCR7 deficiency results in a decrease in medullary enrichment of CD4SP SM and M1+M2 subsets, while no significant difference was observed for DP CD3<sup>lo</sup>CD69<sup>+</sup> subset (Figure 5C). We also added data from these new imaging experiments to the dataset graphed in Figure 5B. Despite the difference revealed via paired analyses, the compiled data continue to indicate that CD4SP SM cells rely on a combination of CCR4 and CCR7 signaling to accumulate in the medulla, and only single CCR4 deficiency significantly impairs medullary entry of the CD4SP SM subset. Additional new imaging data in Figure 5B also confirm that CCR4 is uniquely required for medullary accumulation of post-positive selection DP CD3<sup>lo</sup>CD69<sup>+</sup> cells, as both <italic>Ccr4</italic><sup>-/-</sup> and <italic>Ccr4<sup>-/-</sup>Ccr7<sup>-/-</sup></italic> cells distribute evenly with a medullary:cortical density ration of ~1. We now incorporate these additional data in our manuscript and think these enhanced findings strengthen our conclusion about the critical role of CCR4 in inducing early medullary entry and CCR7 in inducing late medullary entry.</p><disp-quote content-type="editor-comment"><p>Figure 6C, D: These experiments measured caspase 3 cleavage in thymocyte subpopulations. Caspase 3 cleavage reflects apoptosis of thymocytes induced by various signals including glucocorticoid hormones (Alam, et al. J Exp Med. 1997 and Marchetti, et al. Blood 2003). It was also reported that caspase 3 inhibition does not always inhibit the negative selection of thymocytes (Doerfler, et al. J Immunol. 2000). Thus, the figure panels should specify the measurement of caspase 3 cleavage, and the text should convey a careful interpretation of the data with the biology of negative selection.</p></disp-quote><p>We thank the reviewer for the suggestion. It has been established in multiple previous studies that Cleaved Caspase 3 in TCR-signaled thymocytes is an indicator mainly of negative selection (Breed et al., 2019; Hu et al., 2016). However, as the reviewer points out, the intracellular cleaved caspase 3 could reflect apoptosis triggered by other mechanisms as well. Figure 6C has been modified to reflect the measurement of % Cleaved Caspase 3<sup>+</sup> on the graph axes and title, and we have modified our text to acknowledge that while apoptosis of TCR-signaled post-positive selection Ccasp3<sup>+</sup> thymocytes is consistent with detection of negative selection, it could also reflect some apoptosis induced by additional signals like glucocorticoids.</p><disp-quote content-type="editor-comment"><p>Figure 7A, B: Some DCs, including cDC2, are reported to be localized in the cortex within the thymus (Baba, et al., J Immunol. 2009). Also, thymocyte-DC interactions in the cortex are visualized to be CCR7-dependent (Ladi, et al. J Immunol. 2008). Whether cDC2 and CCR7+ cDCs are localized in the thymic cortex or the medulla is important to verify the possibility that CCR4 promotes the medullary migration of thymocytes. CCR4 may be more important for thymocyte-DC interaction in the cortex for the early phase of negative selection than promoting thymocyte migration to the medulla.</p></disp-quote><p>We thank the reviewer for this comment. While the majority of CD11c<sup>+</sup> DCs are enriched in the medulla, some are present in the cortex. Our data show that thymic cDCs do not express CCR7 ligands, and instead CCR7 ligands are expressed by mTECs (Figure 7E), consistent with previous reports (Ki et al., 2014; Kozai et al., 2017). These data are not consistent with CCR7-dependent thymocyte-DC interactions in the cortex. To investigate whether CCR4 ligands constitute a chemokine gradient that would promote chemotaxis towards the medulla, we performed a CCL22 immunofluorescent stain on thymic sections (Figure 2—figure supplement 2) and found that CCL22 protein is concentrated in the medulla, similar to the distribution of CCL19 and CCL21 in the thymic medulla (Kozai et al., 2017; Ueno et al., 2002; Ueno et al., 2004). Therefore, the gradient of CCL22 in the medulla is consistent with CCR4-mediated chemotaxis of post-positive selection thymocytes subsets into the medulla, which we now discuss. However, we also modified the text to acknowledge that CCR4 could induce interactions between post-positive selection thymocytes and sparse DCs in the cortex, which is particularly interesting as both DP CD3<sup>lo</sup>CD69<sup>+</sup> and CD4SP SM cells respond to CCR4 ligands and migrate both in the cortex and medulla.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>1. In Figure 6, the authors examine 'early-phase' and 'late-phase' clonal deletion in various mice. Measurement of 'early-phase' clonal deletion does not appear to be impacted by combined CCR4/CCR7 deficiency. Can the authors comment on this finding?</p></disp-quote><p>We thank the reviewer for raising this point; a subtle, but not significant decrease in early-phase negative selection was observed between WT and <italic>Ccr4<sup>-/-</sup>Ccr7<sup>-/-</sup></italic> DKO mice in the original figure. To further test whether double-deficiency does impact early-phase negative selection, as expected by our model, we analyzed additional <italic>Ccr4<sup>-/-</sup>Ccr7<sup>-/-</sup></italic> mice. These additional data demonstrate that combined CCR4 and CCR7 deficiency induces a statistically significant decrease in early-phase negative selection (Figure 6C). This result solidified our findings that CCR4 is important for early-phase negative selection, and we now discuss these updated data in our revised manuscript.</p><disp-quote content-type="editor-comment"><p>2. Generally, the impact of CCR4 signaling on thymocyte 'outputs' is modest in comparison to CCR7 signaling (migration – Figure 2, medullary accumulation – Figure 5). This doesn't appear to be discussed. Is this due to the stage of the thymocyte stage and that TCR signaled DP and SM thymocytes are less responsive generally or do the authors think there are other factors? This may be pertinent to the authors' findings of reduced responsiveness of more immature, TCR signaled cells to CXCR4 ligands.</p></disp-quote><p>We thank the reviewer for this insight. It is possible that the different magnitude of chemotactic responses induced by CCR4, CCR7 and CXCR4 could reflect intrinsic differences in responsiveness of immature and mature thymocytes to chemokine signals, as suggested by the much lower migration of CD4SP SM relative to CD4SP M1 and M2 to CCR7 ligands. To address this possibility, we investigated the ability of thymocyte subsets to undergo chemotaxis to CCL25, the ligand for CCR9, which has been shown to induce chemotaxis in all but the most mature thymocyte subsets (Campbell, Pan, et al., 1999). We found that CD4SP SM cells migrated as robustly to CCL25 as both earlier DP CD3<sup>lo</sup>CD69<sup>+</sup> cells and later CD4SP M1 cells, indicating that CD4SPSM cells do not have an inherently inefficient ability to respond to chemotactic cues (Figure 2—figure supplement 2). These data are also consistent with migration of CD4SP SM cells to CCR4 ligands at near maximal levels (Figure 2B). Therefore, it is unlikely that CD4SP SM cells are unresponsive to all chemokine signals, but are rather insensitive to specific chemokine stimulation, as seen by their lack of robust responses to CXCR4 or CCR7 ligands (Figure 2D and Figure 3), despite strong expression of these chemokine receptors by this subset. We now discuss these additional findings. While resolving why this CD4SP SM subset responds to some chemokines, but not others for which receptors are expressed is of great interest, and will further our understanding of how chemokine receptors orchestrate thymocyte movement and selection in the thymus, it is beyond the scope of this study, but worthy of further investigation.</p><disp-quote content-type="editor-comment"><p>3. Throughout the manuscript the authors refer to DP CD3lo CD69+ cells and DP CD3+ CD69+ cells as post-positive selection. In a polyclonal repertoire, separating &quot;TCR signaled&quot; (CD69+) thymocytes into those that received positive selection signals versus negative selection signals is difficult. This description of 'post-positive selection' seems inaccurate and unsubstantiated. Have the authors examined Helios expression or expression of other markers (Nur77) to bolster their descriptions?</p></disp-quote><p>The reviewer raises an interesting point that the observed DP CD3<sup>lo</sup>CD69<sup>+</sup> and DP CD3<sup>+</sup>CD69<sup>+</sup> thymocytes may not be representative of post-positive selection cells, but rather cells that could be signaled through the TCR to undergo negative selection at the DP stage. Previous studies showed that thymocytes undergoing signaling that drives negative selection exhibit TCR signaling strength similar to endogenous self-reactive Tregs, measured by Nur77-GFP reporter levels (Stritesky et al., 2013). Thus, to test whether DP CD3<sup>lo</sup>CD69<sup>+</sup> cells reflect mainly cells that have received positive selection TCR signals, versus cells undergoing TCR signaling reflecting negative selection, we compared Nur77-GFP reporter levels of DP CD3<sup>lo</sup>CD69<sup>+</sup> and DP CD3<sup>+</sup>CD69<sup>+</sup> thymocytes with that of thymic Treg precursors (Figure 1—figure supplement 1). Levels of Nur77-GFP in both DP subsets were substantially lower than in Tregs, indicating that these cells largely do not reflect cells undergoing high-avidity TCR signaling associated with negative selection. This finding is consistent with the low frequency, ~ 0.3%, of DP CD69<sup>+</sup> cells that are undergoing apoptosis, reflected by cleaved caspase 3 expression (Figure 6C). We have now modified the text to discuss this point.</p><disp-quote content-type="editor-comment"><p>4. This is a minor point, but when the authors are discussing the cell populations present/absent in b2m-/- mice, there are obviously cells restricted by non-classical MHC-I as well as classical MHC-I that would be impacted. This should be appropriately considered (lines 102-118 for instance).</p></disp-quote><p>We thank the reviewer for the insight. Development of non-classical MHC-I restricted thymocytes, including iNKT cells and CD8αα+ IELps, are disrupted in <italic>β2m<sup>-/-</sup></italic> mice (Bendelac et al., 1994; Ruscher et al., 2017). We have modified the manuscript as suggested to acknowledge this point.</p><disp-quote content-type="editor-comment"><p>5. In the legend of figure 5 (or figure 5 itself), the time point of analysis does not appear to be stated.</p></disp-quote><p>We apologize for this omission and have clarified in the figure legend that the slices were imaged between 1-4 hours after introduction of thymocytes. We did not observe any significant changes in the efficiency of thymocyte accumulation in the medulla within this time frame when analyzing localization of sorted subsets.</p><p>References:</p><p>Au-Yeung, B. B., Melichar, H. J., Ross, J. O., Cheng, D. A., Zikherman, J., Shokat, K. M., Robey, E. A., and Weiss, A. (2014). Quantitative and temporal requirements revealed for Zap70 catalytic activity during T cell development. <italic>Nat Immunol</italic>, <italic>15</italic>(7), 687-694. https://doi.org/10.1038/ni.2918</p><p>Bendelac, A., Killeen, N., Littman, D. R., and Schwartz, R. H. (1994). A subset of CD4<sup>+</sup> thymocytes selected by MHC class I molecules. <italic>Science</italic>, <italic>263</italic>(5154), 1774-1778. https://doi.org/10.1126/science.7907820</p><p>Breed, E. R., Watanabe, M., and Hogquist, K. A. (2019). Measuring Thymic Clonal Deletion at the Population Level. <italic>J Immunol</italic>, <italic>202</italic>(11), 3226-3233. https://doi.org/10.4049/jimmunol.1900191</p><p>Britschgi, M. R., Link, A., Lissandrin, T. K. A., and Luther, S. A. (2008). Dynamic Modulation of CCR7 Expression and Function on Naive T Lymphocytes in vivo1. <italic>The Journal of Immunology</italic>, <italic>181</italic>(11), 7681-7688. https://doi.org/10.4049/jimmunol.181.11.7681</p><p>Campbell, J. J., Haraldsen, G., Pan, J., Rottman, J., Qin, S., Ponath, P., Andrew, D. P., Warnke, R., Ruffing, N., Kassam, N., Wu, L., and Butcher, E. C. (1999). The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. <italic>Nature</italic>, <italic>400</italic>(6746), 776-780. https://doi.org/10.1038/23495</p><p>Campbell, J. J., Pan, J., and Butcher, E. C. (1999). Cutting edge: developmental switches in chemokine responses during T cell maturation. <italic>J Immunol</italic>, <italic>163</italic>(5), 2353-2357. https://doi.org/ji_v163n5p2353 [pii]</p><p>Cowan, J. E., McCarthy, N. I., Parnell, S. M., White, A. J., Bacon, A., Serge, A., Irla, M., Lane, P. J., Jenkinson, E. J., Jenkinson, W. E., and Anderson, G. (2014). Differential requirement for CCR4 and CCR7 during the development of innate and adaptive alphabetaT cells in the adult thymus. <italic>J Immunol</italic>, <italic>193</italic>(3), 1204-1212. https://doi.org/10.4049/jimmunol.1400993</p><p>Davalos-Misslitz, A. C., Rieckenberg, J., Willenzon, S., Worbs, T., Kremmer, E., Bernhardt, G., and Forster, R. (2007). Generalized multi-organ autoimmunity in CCR7-deficient mice. <italic>Eur J Immunol</italic>, <italic>37</italic>(3), 613-622. https://doi.org/10.1002/eji.200636656</p><p>Davalos-Misslitz, A. C., Worbs, T., Willenzon, S., Bernhardt, G., and Forster, R. (2007). Impaired responsiveness to T-cell receptor stimulation and defective negative selection of thymocytes in CCR7-deficient mice. <italic>Blood</italic>, <italic>110</italic>(13), 4351-4359. https://doi.org/10.1182/blood-2007-01-070284</p><p>Doerfler, P., Forbush, K. A., and Perlmutter, R. M. (2000). Caspase enzyme activity is not essential for apoptosis during thymocyte development. <italic>J Immunol</italic>, <italic>164</italic>(8), 4071-4079. https://doi.org/10.4049/jimmunol.164.8.4071</p><p>Dzhagalov, I. L., Chen, K. G., Herzmark, P., and Robey, E. A. (2013). Elimination of self-reactive T cells in the thymus: a timeline for negative selection. <italic>PLoS Biol</italic>, <italic>11</italic>(5), e1001566. https://doi.org/10.1371/journal.pbio.1001566</p><p>Ehrlich, L. I., Oh, D. Y., Weissman, I. L., and Lewis, R. S. (2009). Differential contribution of chemotaxis and substrate restriction to segregation of immature and mature thymocytes. <italic>Immunity</italic>, <italic>31</italic>(6), 986-998. https://doi.org/10.1016/j.immuni.2009.09.020</p><p>Hu, D. Y., Yap, J. Y., Wirasinha, R. C., Howard, D. R., Goodnow, C. C., and Daley, S. R. (2016). A timeline demarcating two waves of clonal deletion and Foxp3 upregulation during thymocyte development. <italic>Immunol Cell Biol</italic>, <italic>94</italic>(4), 357-366. https://doi.org/10.1038/icb.2015.95</p><p>Hu, Z., Lancaster, J. N., Sasiponganan, C., and Ehrlich, L. I. (2015). CCR4 promotes medullary entry and thymocyte-dendritic cell interactions required for central tolerance. <italic>J Exp Med</italic>, <italic>212</italic>(11), 1947-1965. https://doi.org/10.1084/jem.20150178</p><p>Kadakia, T., Tai, X., Kruhlak, M., Wisniewski, J., Hwang, I. Y., Roy, S., Guinter, T. I., Alag, A., Kehrl, J. H., Zhuang, Y., and Singer, A. (2019). E-protein-regulated expression of CXCR4 adheres preselection thymocytes to the thymic cortex. <italic>J Exp Med</italic>, <italic>216</italic>(8), 1749-1761. https://doi.org/10.1084/jem.20182285</p><p>Ki, S., Park, D., Selden, H. J., Seita, J., Chung, H., Kim, J., Iyer, V. R., and Ehrlich, L. I. R. (2014). Global transcriptional profiling reveals distinct functions of thymic stromal subsets and age-related changes during thymic involution. <italic>Cell Rep</italic>, <italic>9</italic>(1), 402-415. https://doi.org/10.1016/j.celrep.2014.08.070</p><p>Kimura, M. Y., Thomas, J., Tai, X., Guinter, T. I., Shinzawa, M., Etzensperger, R., Li, Z., Love, P., Nakayama, T., and Singer, A. (2016). Timing and duration of MHC I positive selection signals are adjusted in the thymus to prevent lineage errors. <italic>Nat Immunol</italic>, <italic>17</italic>(12), 1415-1423. https://doi.org/10.1038/ni.3560</p><p>Kozai, M., Kubo, Y., Katakai, T., Kondo, H., Kiyonari, H., Schaeuble, K., Luther, S. A., Ishimaru, N., Ohigashi, I., and Takahama, Y. (2017). Essential role of CCL21 in establishment of central self-tolerance in T cells. <italic>J Exp Med</italic>, <italic>214</italic>(7), 1925-1935. https://doi.org/10.1084/jem.20161864</p><p>Kurobe, H., Liu, C., Ueno, T., Saito, F., Ohigashi, I., Seach, N., Arakaki, R., Hayashi, Y., Kitagawa, T., Lipp, M., Boyd, R. L., and Takahama, Y. (2006). CCR7-dependent cortex-to-medulla migration of positively selected thymocytes is essential for establishing central tolerance. <italic>Immunity</italic>, <italic>24</italic>(2), 165-177. https://doi.org/10.1016/j.immuni.2005.12.011</p><p>Kwan, J., and Killeen, N. (2004). CCR7 directs the migration of thymocytes into the thymic medulla. <italic>J Immunol</italic>, <italic>172</italic>(7), 3999-4007. https://doi.org/10.4049/jimmunol.172.7.3999</p><p>Lancaster, J. N., Thyagarajan, H. M., Srinivasan, J., Li, Y., Hu, Z., and Ehrlich, L. I. R. (2019). Live-cell imaging reveals the relative contributions of antigen-presenting cell subsets to thymic central tolerance. <italic>Nat Commun</italic>, <italic>10</italic>(1), 2220. https://doi.org/10.1038/s41467-019-09727-4</p><p>Lutes, L. K., Steier, Z., McIntyre, L. L., Pandey, S., Kaminski, J., Hoover, A. R., Ariotti, S., Streets, A., Yosef, N., and Robey, E. A. (2021). T cell self-reactivity during thymic development dictates the timing of positive selection. <italic>ELife</italic>, <italic>10</italic>, 1-28. https://doi.org/10.7554/<italic>eLife</italic>.65435</p><p>Melichar, H. J., Ross, J. O., Herzmark, P., Hogquist, K. A., and Robey, E. A. (2013). Distinct temporal patterns of T cell receptor signaling during positive versus negative selection in situ. <italic>Sci Signal</italic>, <italic>6</italic>(297), ra92. https://doi.org/10.1126/scisignal.2004400</p><p>Nitta, T., Nitta, S., Lei, Y., Lipp, M., and Takahama, Y. (2009). CCR7-mediated migration of developing thymocytes to the medulla is essential for negative selection to tissue-restricted antigens. <italic>Proc Natl Acad Sci U S A</italic>, <italic>106</italic>(40), 17129-17133. https://doi.org/10.1073/pnas.0906956106</p><p>Ross, J. O., Melichar, H. J., Au-Yeung, B. B., Herzmark, P., Weiss, A., and Robey, E. A. (2014). Distinct phases in the positive selection of CD8<sup>+</sup> T cells distinguished by intrathymic migration and T-cell receptor signaling patterns. <italic>Proc Natl Acad Sci U S A</italic>, <italic>111</italic>(25), E2550-2558. https://doi.org/10.1073/pnas.1408482111</p><p>Ruscher, R., Kummer, R. L., Lee, Y. J., Jameson, S. C., and Hogquist, K. A. (2017). CD8alphaalpha intraepithelial lymphocytes arise from two main thymic precursors. <italic>Nat Immunol</italic>, <italic>18</italic>(7), 771-779. https://doi.org/10.1038/ni.3751</p><p>Saini, M., Sinclair, C., Marshall, D., Tolaini, M., Sakaguchi, S., and Seddon, B. (2010). Regulation of Zap70 expression during thymocyte development enables temporal separation of CD4 and CD8 repertoire selection at different signaling thresholds. <italic>Sci Signal</italic>, <italic>3</italic>(114), ra23. https://doi.org/10.1126/scisignal.2000702</p><p>Stritesky, G. L., Xing, Y., Erickson, J. R., Kalekar, L. A., Wang, X., Mueller, D. L., Jameson, S. C., and Hogquist, K. A. (2013). Murine thymic selection quantified using a unique method to capture deleted T cells. <italic>Proc Natl Acad Sci U S A</italic>, <italic>110</italic>(12), 4679-4684. https://doi.org/10.1073/pnas.1217532110</p><p>Ueno, T., Hara, K., Willis, M. S., Malin, M. A., Hopken, U. E., Gray, D. H., Matsushima, K., Lipp, M., Springer, T. A., Boyd, R. L., Yoshie, O., and Takahama, Y. (2002). Role for CCR7 ligands in the emigration of newly generated T lymphocytes from the neonatal thymus. <italic>Immunity</italic>, <italic>16</italic>(2), 205-218. https://doi.org/10.1016/s1074-7613(02)00267-4</p><p>Ueno, T., Saito, F., Gray, D. H., Kuse, S., Hieshima, K., Nakano, H., Kakiuchi, T., Lipp, M., Boyd, R. L., and Takahama, Y. (2004). CCR7 signals are essential for cortex-medulla migration of developing thymocytes. <italic>J Exp Med</italic>, <italic>200</italic>(4), 493-505. https://doi.org/10.1084/jem.20040643</p></body></sub-article></article>